N, N-diarylurea derivative and application thereof

By developing N,N-diarylurea compounds, the problem of lack of NEK7 and AIM-2 agonists in the prior art was solved, and the binding of NEK7 and NLRP3 was blocked, and the formation and activation of inflammasomes were inhibited, providing New research directions for the treatment of inflammation and tumors.

CN119060018APending Publication Date: 2024-12-03HANGZHOU BIO CREATIVITY PHARM TECH CO LTD
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202410700472.1
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2023-06-02
Filing Date
2024-05-31
Publication Date
2024-12-03

AI Technical Summary

Technical Problem

There is a lack of effective NEK7 inhibitors and AIM-2 agonists in the prior art, which makes it difficult to block NEK7 and NLRP3-mediated inflammatory responses, and no compounds can simultaneously activate the AIM-2 inflammasome pathway.

Method used

A new structural N,N-diarylurea compound was developed as a NEK7 inhibitor and AIM-2 agonist to block the binding of NEK7 and NLRP3, thereby inhibiting the formation and activation of inflammasomes, with Potential for the treatment of NEK7 and AIM-2-related diseases.

Benefits of technology

This compound effectively promotes the activation of AIM-2 inflammasomes in vitro, provides new tools and directions for the research of inflammatory diseases and malignant tumors, and has broad pharmaceutical application prospects.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004870903070000011
    Figure BDA0004870903070000011
  • Figure BDA0004870903070000012
    Figure BDA0004870903070000012
  • Figure BDA0004870903070000021
    Figure BDA0004870903070000021
Patent Text Reader

Abstract

The invention discloses N, N-diarylurea compounds and application thereof, and particularly relates to the derivatives and prodrugs, tautomers, optical isomers, solvates, isotope derivatives or pharmaceutically acceptable salts thereof, the compounds have NEK7 inhibitory activity, can block formation of NLRP3 inflammasomes, can activate AIM2 inflammasome signaling pathways, and can be used for preparing medicines for treating inflammatory diseases. The compound can be used for treating NEK7 and NLRP3 induced diseases or AIM-2 inflammasome related diseases, and has a wide application prospect.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention belongs to the field of pharmaceutical chemistry and relates to an N,N-diaryl urea compound and a preparation method and application thereof. The compound and its pharmaceutically acceptable salts, isotope derivatives, solvates or isomers have NEK7 inhibitory activity and can block the formation of NLRP3 inflammasomes, while activating AIM-2 inflammasomes, and can be used to treat diseases induced by NEK7 and NLRP3 and diseases related to AIM-2 inflammasomes, and have broad application prospects. Background Art

[0002] NEK7 is a member of the NIMA-associated kinase (NEKs) family. It is widely expressed in various tissues such as the heart, liver, lung, brain, muscle, testis, leukocytes, and spleen, and plays an important role in cell cycle regulation and mitosis. In addition, NEK7 has also been shown to be a key member of the NLRP3 inflammasome pathway and is involved in the assembly and activation of the NLRP3 inflammasome. It promotes oligomerization of the complex by binding to the leucine-rich repeat (LRR) domain of NLRP3. The complex binds to the ASC protein through the PYD domain, thereby recruiting Pro-Caspase-1 and completing the self-cleavage process, releasing activated Caspase-1. Activated Caspase-1 can cleave the precursors of IL-1β and IL-18, promoting the production of IL-1β and IL-18; in addition, activated Caspase-1 will also cleave the GSDMD protein to release the N-terminus of GSDMD, which can be translocated to the cell membrane and destroy the cell membrane structure to produce holes; inflammatory factors such as IL-1β and IL-18 and cell contents will be released to the extracellular space through the holes, causing cell pyroptosis and a series of immune responses. Blocking the binding of NEK7 protein and NLRP3 can destroy the assembly of inflammasomes and promote their decomposition, thereby inhibiting the activation of downstream Caspase-1, the production and release of IL-1β and IL-18, and the occurrence of cell pyroptosis. So far, there has been little research and progress on NEK7 inhibitors. Only a series of NEK7 inhibitors containing urea structures have been reported in the patent published by Halia Therapeutics (WO2021226547), among which the representative compound Ib-4 showed good in vitro activity in inhibiting the release of IL-1β, and the structure is shown in the figure below:

[0003]

[0004] Melanoma deficiency factor 2 (AIM2) is an intracellular DNA sensor and one of the important pattern recognition receptors that make up the inflammasome. It plays an important role in the innate immune response. The AIM2 protein consists of an N-terminal pyrin domain (PYD) and a C-terminal hematopoietic interferon-induced nuclear protein (HIN200) domain with a 200 amino acid repeat sequence. It is mainly located in the cytoplasm and belongs to the PYHIN protein family. In recent years, research on the AIM2 inflammasome has attracted more and more attention. It is the first inflammasome with a clear ligand. Its ligand dsDNA is ubiquitous in organisms and is regionally distributed in eukaryotic cells, making AIM2 an important cytoplasmic sensor for the destruction of the intracellular homeostasis and the invasion of pathogens.

[0005] Currently, there is no report on a compound that can act as a NEK7 inhibitor and / or AIM-2 agonist.

[0006] The present invention provides a series of compounds as agonists of the AIM-2 inflammasome pathway, which can effectively promote the activation of the AIM-2 pathway in vitro, which has not been previously reported in domestic and foreign studies. The compounds provided by the present invention provide new tools for exploring AIM2-related signaling pathways, and also provide new ideas for future new drug research on inflammatory diseases and malignant tumors. Summary of the invention

[0007] The present invention provides a novel N,N-diaryl urea compound, which can be used as a NEK7 inhibitor and / or an AIM-2 agonist for preparing a drug for treating diseases or conditions mediated by NEK7 or associated with AIM-2 inflammasomes and related diseases or conditions.

[0008] In one aspect, the present invention provides a compound represented by formula (I) or a pharmaceutically acceptable salt, isotopic derivative, solvate or isomer thereof:

[0009]

[0010] in:

[0011] Ring A is selected from pyrazole, benzene ring, pyridine or pyrimidine:

[0012] R 1 Selected from hydrogen, halogen, cyano, hydroxyl, amino, mercapto, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkylsulfone, -CO-NH-(C 1-6alkyl), -CO-NH-(C 3-6 Cycloalkyl), 4-10 membered heterocyclic group, C 6-12 Aryl, 5-14 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkylsulfone, 4-10 membered heterocyclic group, C 6-12 Aryl and 5-14 membered heteroaryl are unsubstituted or substituted by one or more of the following substituents: halogen, cyano, hydroxyl, amino, mercapto, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio, C 1-6 Alkylamino, 4-10 membered heterocyclic, C 6-12 Aryl, 5--14-membered heteroaryl;

[0013] n is selected from 0, 1, 2 or 3;

[0014] Ring B is selected from a benzene ring, a pyridine ring, a pyrimidine ring, a pyrazine ring or a pyridazine ring;

[0015] R 2 Selected from hydrogen, halogen, cyano, hydroxyl, amino, mercapto, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkylsulfone, -CO-NH-(C 1-6 alkyl), -CO-NH-(C 3-6 cycloalkyl) or a 4-8 membered heterocyclic group; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6The alkylsulfone group or the 4-8 membered heterocyclic group is unsubstituted or substituted by one or more of the following substituents: halogen, cyano, hydroxyl, amino, mercapto, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio, C 1-6 Alkylamino;

[0016] m is selected from 0, 1, 2 or 3;

[0017] L is selected from O, CR 1a R 1b or NR 1c ;

[0018] R 1a and R 1b are each independently selected from hydrogen, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, hydroxyl, amino, cyano, C 1-6 Alkoxy, C 1-6 Alkylamino; R 1a and R 1b They may also be connected to each other to form a 3-8 membered aliphatic ring or heterocyclic ring, wherein the aliphatic ring and heterocyclic ring may be saturated or unsaturated;

[0019] R 1c Selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C 3-6 Cycloalkyl;

[0020] Ring C is selected from the following structures:

[0021]

[0022] Wherein, X and Y are each independently selected from N or CR 2a ;

[0023] R 2a is selected from hydrogen, halogen, cyano, hydroxy, difluoromethoxy, trifluoromethoxy, amino, thiol, trifluoromethylthio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C1-6 Alkylamino;

[0024] R 3 is selected from hydrogen, halogen, cyano, hydroxy, difluoromethoxy, trifluoromethoxy, amino, thiol, trifluoromethylthio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino;

[0025] R 4 Selected from cyano, hydroxyl, amino, C 1-6 Alkoxy, C 1-6 Alkylamino, -NH-CO-(C 1-6 Alkyl), -NH-CO-(C 3-6 Cycloalkyl), -NH-SO2-(C 1-6 Alkyl), -NH-SO2-(C 3-6 Cycloalkyl), -CO-NH-(C 1-6 Alkyl) or -CO-NH-(C 3-6 Cycloalkyl);

[0026] R 3 and R 4 They can also be connected to form a 6-8 membered heterocyclic or aromatic heterocyclic ring; the R 3 and R 4 The 6-8 membered heterocyclic or aromatic heterocyclic ring formed by connecting to each other may be unsubstituted or substituted by one or more of the following substituents: halogen, cyano, hydroxyl, difluoromethoxy, trifluoromethoxy, amino, mercapto, trifluoromethylthio, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio, C 1-6 Alkylamino;

[0027] Q 1 =C or N;

[0028] Q 2 ,Q 3 ,Q 4 ,Q 5 Each independently selected from CH, CR 2b , N, NR 2b , O or S, and the total number of N does not exceed 2, and the number of O and S does not exceed 1 respectively;

[0029] R 2b is selected from hydrogen, halogen, cyano, hydroxy, difluoromethoxy, trifluoromethoxy, amino, thiol, trifluoromethylthio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, carboxyl, -CONH2, -NH-CO-(C 1-6 Alkyl), -NH-CO-(C 3-6 Cycloalkyl), -CO-NH-(C 1-6 Alkyl) or -CO-NH-(C 3-6 cycloalkyl).

[0030] In some embodiments, Ring A in the general formula (I) is selected from the following groups:

[0031]

[0032] In some embodiments, the compound represented by formula (I), wherein the ring C is selected from:

[0033]

[0034] On the other hand, the present invention provides a compound having a structure shown in the following formula (II), or a pharmaceutically acceptable salt, isotope derivative, solvate, or a stereoisomer, geometric isomer, tautomer, or a prodrug molecule or metabolite thereof:

[0035]

[0036] in:

[0037] m is selected from 0, 1, 2 or 3;

[0038] X1 and Y1 are each independently selected from N or CR 2 ;

[0039] Z is selected from N or CR 2a ;

[0040] L is selected from O, CR 1a R 1b or NR 1c ;

[0041] Cy is selected from the group consisting of one or more R Y Substituted 4-10 membered heterocyclic group, C 6-12 Aryl or 5-14 membered heteroaryl;

[0042] R Y is selected from hydrogen, halogen, cyano, hydroxyl, amino, mercapto, oxo, or may be replaced by one or more R 3a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio, C 1-6 Alkylamino, 4-10 membered heterocyclic, C 6-12 Aryl, 5-14 membered heteroaryl;

[0043] or any two R Y and the atoms to which they are connected are combined to form a C3-C6 cycloalkyl or a 4-8 membered heterocyclic group, wherein the C3-C6 cycloalkyl or the 4-8 membered heterocyclic group may be optionally replaced by one or more R 3a replace;

[0044] R 1 Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkylsulfone, -CO-NH-(C 1-6 Alkyl), -CO-NH-(C 3-6 Cycloalkyl), 4-10 membered heterocyclic group, C 6-12 Aryl or 5-14 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkylsulfone, 4-10 membered heterocyclic group, C 6-12 The aryl or 5-14 membered heteroaryl may be optionally substituted by one or more of the following substituents: halogen, cyano, hydroxy, amino, mercapto, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio, C1-6 Alkylamino, 4-10 membered heterocyclic, C 6-12 Aryl or 5-14 membered heteroaryl;

[0045] R 2 Each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkylsulfone, -CO-NH-(C 1-6 alkyl), -CO-NH-(C 3-6 cycloalkyl) or a 4-8 membered heterocyclic group; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 The alkylsulfone group or the 4-8 membered heterocyclic group is unsubstituted or substituted by one or more of the following substituents: halogen, cyano, hydroxyl, amino, mercapto, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio or C 1-6 Alkylamino;

[0046] R 3 is selected from cyano, ethynyl or cyclopropyl, wherein the ethynyl or cyclopropyl may be optionally replaced by C 1-6 Alkyl, C 1-6 Hydroxyalkyl, 4-10 membered heterocyclic group or C 3-8 Cycloalkyl substitution;

[0047] R 1a and R 1b are each independently selected from hydrogen, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, hydroxyl, amino, cyano, C 1-6 Alkoxy, C 1-6 Alkylamino;

[0048] Or, R 1aand R 1b The atoms to which they are connected may also be connected to each other to form a 3-8 membered aliphatic ring or heterocyclic ring, wherein the aliphatic ring and heterocyclic ring may be saturated or unsaturated;

[0049] R 1c Selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C 3-6 Cycloalkyl;

[0050] R 2a is selected from hydrogen, halogen, cyano, hydroxy, difluoromethoxy, trifluoromethoxy, amino, thiol, trifluoromethylthio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino;

[0051] R 3a , R 4a Each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 an alkylsulfone group, or a 4-8 membered heterocyclic group.

[0052] In some embodiments, the compound represented by formula (II), or a pharmaceutically acceptable salt, isotope derivative, solvate, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, or a metabolite thereof, has a structure represented by the following formula (III), or a pharmaceutically acceptable salt, isotope derivative, solvate, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, or a metabolite thereof:

[0053]

[0054] Among them, the R 1 ,Cy,X1,Y1,m,R3,L,R 4a The definition of is as defined in the general formula (II).

[0055] In a further embodiment, the compound represented by formula (III), or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, or a metabolite thereof, has a structure represented by the following formula (IIIA) or (IIIB), or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, or a metabolite thereof:

[0056]

[0057] Among them, the R 1 、Cy、X1、Y1、m、R3、R 4a The definition of is as defined in the general formula (II).

[0058] In some embodiments, the compound of formula (II), (III), (IIIA) or (IIIB), wherein X1 or Y1 is independently selected from CR 2 .

[0059] In some embodiments, the compound of formula (II), (III), (IIIA) or (IIIB), wherein R 2 Each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or C 1-6 Alkylsulfone group, the R 4a Each independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl or C 1-6 Alkoxy, wherein m is 1 or 2.

[0060] In a further embodiment, the R 2 is selected from hydrogen, halogen, methyl or methoxy.

[0061] In some embodiments, the compound of formula (II), (III), (IIIA) or (IIIB), wherein X1 or Y1 is independently selected from CH.

[0062] In some embodiments, the compound of formula (II), (III), (IIIA) or (IIIB), wherein R 3 is selected from cyano, ethynyl or cyclopropyl, wherein the ethynyl and cyclopropyl groups may be optionally replaced by one or more C1-6 Alkyl or C 1-6 Hydroxyalkyl substituted.

[0063] In a further embodiment, the R 3 Selected from

[0064]

[0065] In some embodiments, the compound of formula (II), (III), (IIIA) or (IIIB), wherein R 1 Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group; 1-6 Alkyl, C 3-6 The cycloalkyl or 4-10 membered heterocyclic group may be substituted by one or more of the following substituents: hydrogen, halogen, cyano, hydroxyl, amino, mercapto, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio, C 1-6 Alkylamino or 4-10 membered heterocyclic group.

[0066] In a further embodiment, the R 1 Each independently selected from C 1-6 Alkyl or C 3-6 Cycloalkyl; said C 1-6 Alkyl, C 3-6 The cycloalkyl group may be optionally substituted with one or more of the following substituents: hydrogen, cyano, hydroxy, amino, mercapto, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio or C 1-6 Alkylamino.

[0067] In a further embodiment, the R 1 Selected from

[0068]

[0069] In some embodiments, the compound of formula (II), (III), (IIIA) or (IIIB), wherein the Cy is selected from Y Substituted phenyl, cyclohexyl or pyridyl.

[0070] In a further embodiment, the R Y Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, mercapto, oxo, or may be replaced by one or more R 3a Substituted C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio, C 1-6 Alkylamino or 4-10 membered heterocyclic group;

[0071] or any two R Y and the atoms to which they are connected are combined to form a C3-C6 cycloalkyl or a 4-8 membered heterocyclic group, wherein the C3-C6 cycloalkyl or the 4-8 membered heterocyclic group may be optionally replaced by one or more R 3a replace.

[0072] In a further embodiment, the R 3a Selected from hydrogen, halogen, cyano, hydroxyl, amino, mercapto, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 an alkylsulfone group, or a 4-8 membered heterocyclic group.

[0073] In some embodiments, the compound of formula (II), (III), (IIIA) or (IIIB), wherein the Cy is selected from the following groups:

[0074]

[0075] In some embodiments, the compound represented by the general formula (I), (II), (III), (IIIA) or (IIIB), or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, metabolite thereof, is selected from the following structural compounds:

[0076]

[0077]

[0078]

[0079]

[0080]

[0081] or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, or a metabolite thereof.

[0082] On the other hand, the present invention provides a pharmaceutical composition comprising a compound of formula (I), (II), (III), (IIIA) or (IIIB) or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule or metabolite thereof.

[0083] In another aspect, the present invention provides a compound as described in the above formula (I), (II), (III), (IIIA) or (IIIB) or a pharmaceutically acceptable salt, isotope derivative, solvate, or a stereoisomer, geometric isomer, tautomer, or a prodrug molecule, metabolite or the pharmaceutical composition described above for the preparation of a medicament for treating diseases or disorders mediated by NEK7 or associated with AIM-2 inflammasome and related diseases or disorders.

[0084] The present invention also provides a method for treating a disease or condition, the method comprising administering to a patient in need thereof a therapeutically effective amount of a compound of formula (I), (II), (III), (IIIA) or (IIIB) as described above, or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, metabolite thereof, or the pharmaceutical composition described above.

[0085] In some embodiments, the disease to be treated and / or prevented is a disease mediated by NEK7, which is a chronic inflammatory disease such as gout, nephritis, atherosclerosis, non-alcoholic fatty liver disease, hepatitis, diabetes, enteritis, acute inflammatory diseases such as traumatic brain injury, wounds, toothache, acute nephritis, viral infection, sepsis, burns, septic shock, cardiovascular diseases such as myocardial ischemia, heart failure, nervous system diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, meningitis, headache, neuropathic pain, autoimmune diseases such as rheumatoid arthritis, systemic vasculitis, respiratory system such as COPD, asthma, pneumonia, tuberculosis, metabolic syndrome such as obesity, hyperglycemia, hypertension, dyslipidemia, hyperuricemia, hyperinsulinemia, digestive system such as viral hepatitis, cirrhosis, liver fibrosis, enteritis, tumors and tumor metastasis, tumor complications.

[0086] In some embodiments, the disease to be treated and / or prevented is a disease associated with AIM-2 inflammasome, and the disease is a viral or bacterial infection, a nerve injury, or a tumor.

[0087] Unless otherwise indicated, general chemical terms used in the structural formulae have their usual meanings.

[0088] For example, the term "halogen," as used herein, refers to fluorine, chlorine, bromine, or iodine, unless otherwise specified.

[0089] In the present invention, unless otherwise specified, "alkyl" includes a linear or branched monovalent saturated hydrocarbon group. For example, alkyl includes methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, sec-butyl, tert-butyl, n-pentyl, 3-(2-methyl)butyl, 2-pentyl, 2-methylbutyl, neopentyl, n-hexyl, 2-hexyl, 2-methylpentyl, etc. Similarly, "C 1-6 "Alkyl" in 1-6 ” refers to a group containing 1, 2, 3, 4, 5 or 6 carbon atoms in a straight or branched chain.

[0090] The term "alkoxy" refers to the oxygen ether form of the aforementioned straight-chain or branched alkyl groups, ie, -O-alkyl.

[0091] The term "haloalkyl" refers to an alkyl group in which one or more H has been replaced by a halogen atom.

[0092] The term "haloalkoxy" refers to the radical -O-haloalkyl.

[0093] The term "oxo" or "oxo group" refers to an oxygen atom in the form of a divalent substituent which forms a carbonyl group when attached to C and forms a sulfoxide or sulfone group or an N-oxide group when attached to a heteroatom.

[0094] The term "cycloalkyl" refers to a ring system having at least one cyclized alkyl group. 3-12 Cycloalkyl, more preferably C 3-6 Yuan, among which "C 3-12 " means that the cycloalkyl group may have 3, 4, 5, 6, 7, 8, 9, 10, 11 or 12 ring atoms. The cycloalkyl group may include a monocyclic ring and a polycyclic ring (for example, having 2, 3 or 4 fused rings, spiro rings, bridged rings, etc.). In some embodiments, the cycloalkyl group includes but is not limited to cyclopropyl, cyclobutyl, cyclopentyl, etc.; the cycloalkyl group may also be fused to an aryl, heterocyclic or heteroaryl ring, wherein the ring connected to the parent structure is a cycloalkyl group.

[0095] The term "alkenyl" refers to an alkyl group having one or more carbon-carbon double bonds, for example, ethenyl, propenyl, 1,3-butadiene, cis-butenyl, trans-butenyl, and the like.

[0096] The term "alkynyl" refers to an alkyl group having one or more carbon-carbon triple bonds, for example, ethynyl, propynyl, and the like.

[0097] The term "aryl", in the present invention, unless otherwise specified, refers to an unsubstituted or substituted monocyclic or condensed ring aromatic group containing carbon ring atoms. 6-12 Aryl, more preferably C 6-10 The monocyclic or bicyclic aromatic ring group is preferably phenyl or naphthyl. The aryl ring may be fused to a heteroaryl, heterocyclic or cycloalkyl group, wherein the ring connected to the parent structure is an aryl ring, and non-limiting examples include but are not limited to benzocyclopentyl.

[0098] The term "heteroaryl", in the present invention, unless otherwise specified, refers to a monocyclic or polycyclic (e.g., fused bicyclic) aromatic heterocycle having at least one heteroatom, wherein the heteroatom is selected from N, O and / or S, and wherein the nitrogen or sulfur heteroatom can be selectively oxidized, and the nitrogen heteroatom can be selectively quaternized. Preferably, it is a 5-14-membered heteroaryl, wherein the "5-14 members" in the 5-14-membered heteroaryl refers to a heteroaryl composed of 5-14 ring atoms of C, N, O or S. More preferably, it is a 5-10-membered heteroaryl, and even more preferably, it is a 5-6-membered heteroaryl. Examples of heteroaryl include, but are not limited to, thienyl, furanyl, imidazolyl, isoxazolyl, oxazolyl, pyrazolyl, pyrrolyl, thiazolyl, thiadiazolyl, triazolyl, pyridyl, pyridazinyl, indolyl, azaindolyl, indazolyl, benzimidazolyl, benzofuranyl, benzothienyl, benzisoxazolyl, benzothiazolyl, benzothiazolyl, benzothiadiazolyl, benzotriazolyl adenine, quinolyl or isoquinolyl. The heteroaryl may be fused to an aryl, heterocyclyl or cycloalkyl ring, wherein the ring attached to the parent structure is a heteroaryl ring.

[0099] The term "heterocyclyl" refers to a ring system having at least one cyclized alkyl or cyclized alkenyl group containing a heterocyclic ring, wherein the heteroatom is selected from N, O and / or S. The heterocyclyl may include a monocyclic or polycyclic ring (e.g., having 2, 3 or 4 fused rings, spirocyclic rings, bridged rings, etc.). The heterocyclyl may be connected to the rest of the compound via a ring-forming carbon atom or a ring-forming heteroatom. Preferably, a 3-14-membered heterocyclyl is used, wherein the "3-14-membered" in the 3-14-membered heterocyclyl refers to a heterocyclyl composed of 3-14 C, N, O or S ring atoms; more preferably a 3-6-membered heterocyclyl, and even more preferably a 5-6-membered heterocyclyl; wherein the nitrogen or sulfur heteroatom may be selectively oxidized, and the nitrogen heteroatom may be selectively quaternized. Examples of these heterocyclic groups include, but are not limited to, azetidinyl, pyrrolidinyl, piperidinyl, piperazinyl, oxopiperazinyl, oxopiperidinyl, tetrahydrofuranyl, dioxolanyl, tetrahydroimidazolyl, tetrahydrothiazolyl, tetrahydrooxazolyl, tetrahydropyranyl, morpholinyl, thiomorpholinyl, thiomorpholinyl sulfoxide, thiomorpholinyl sulfone and tetrahydrooxadiazolyl. Spiro heterocycles can be 6-12 membered spiral heterocycles, including but not limited to: 4-azaspiro [2.4] heptane, 4-azaspiro [2.4] heptane. The heterocyclic group can be fused to an aryl, heteroaryl or cycloalkyl ring, wherein the ring connected to the parent structure is a heterocyclic group.

[0100] The term "alkylamino" refers to an open-chain alkyl group containing a nitrogen atom, such as C1-C6 alkylamino, including but not limited to methylamino, ethylamino, isopropylamino, dimethylamino, methylethylamino, diethylamino and the like.

[0101] The term "alkylthio" refers to a straight or branched chain alkyl group attached through a sulfur atom, i.e., -S-alkyl, such as C 1-6 Alkylthio groups include, but are not limited to, methylthio, ethylthio, propylthio (including n-propylthio and isopropylthio), butylthio (including n-butylthio, isobutylthio, sec-butylthio and tert-butylthio), pentylthio (including n-pentylthio, isopentylthio and neopentylthio), hexylthio (n-hexylthio, 2-methylpentylthio, 3-methylpentylthio, 2,3-dimethylbutylthio and 2,2-dimethylbutylthio) and the like.

[0102] The term "alkylsulfonyl" refers to a straight or branched chain alkyl group linked through a sulfone group, i.e., -SO2-alkyl, such as C 1-6 Alkylsulfone groups include, but are not limited to, methylsulfone, ethylsulfone, propylsulfone (including n-propylsulfone and isopropylsulfone), butylsulfone (including n-butylsulfone, isobutylsulfone, sec-butylsulfone and tert-butylsulfone), pentylsulfone (including n-pentylsulfone, isopentylsulfone and neopentylsulfone), hexylsulfone (n-hexylsulfone, 2-methylpentylsulfone, 3-methylpentylsulfone, 2,3-dimethylbutylsulfone and 2,2-dimethylbutylsulfone), and the like.

[0103] The term "cyano" refers to a -CN group.

[0104] The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids.

[0105] The "compounds" described in the present invention include but are not limited to the following forms of compounds: free base, stereoisomers, geometric isomers, tautomers, isotopes, pharmaceutically acceptable salts, solvates, hydrates, prodrugs (esters), etc.

[0106] The "compounds" of the present invention may be asymmetric, for example, having one or more stereoisomers. Unless otherwise indicated, all stereoisomers are included, such as enantiomers and diastereomers. The compounds of the present invention containing asymmetric carbon atoms can be isolated in optically pure form or in racemic form. Optically pure forms can be obtained by resolution of racemic mixtures, synthesis using chiral starting materials or chiral reagents.

[0107] The term "pharmaceutically acceptable" as used herein refers to those compounds, materials, compositions and / or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with human and animal tissues without excessive toxicity, irritation, allergic reactions or other problems or complications, commensurate with a reasonable benefit / risk ratio.

[0108] The term "pharmaceutically acceptable salt" refers to salts of compounds of the present invention, prepared from compounds with specific substituents discovered by the present invention with relatively non-toxic acids or bases. When the compounds of the present invention contain relatively acidic functional groups, base addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of base in a pure solution or a suitable inert solvent. Pharmaceutically acceptable base addition salts include sodium, potassium, calcium, ammonium, organic amine or magnesium salts or similar salts. When the compounds of the present invention contain relatively basic functional groups, acid addition salts can be obtained by contacting the neutral form of such compounds with a sufficient amount of acid in a pure solution or a suitable inert solvent. Certain specific compounds of the present invention contain basic and acidic functional groups and can be converted into either base or acid addition salts.

[0109] Pharmaceutically acceptable salts of the present invention can be synthesized by conventional chemical methods from parent compounds containing acid radicals or bases. Generally, the preparation method of such salts is: in water or an organic solvent or a mixture of the two, these compounds in free acid or base form are reacted with a stoichiometric amount of an appropriate base or acid to prepare.

[0110] When the compound provided by the invention is an acid, its corresponding salt can be conveniently obtained from pharmaceutically acceptable nontoxic alkalis, including inorganic bases and organic bases. Salts derived from inorganic bases include salts of aluminum, ammonium, calcium, copper (high and low valence), ferric iron, ferrous iron, lithium, magnesium, manganese (high and low valence), potassium, sodium, zinc and the like. Particularly preferred are salts of ammonium, calcium, magnesium, potassium and sodium. Nontoxic organic bases that can be derived into pharmaceutically acceptable salts include primary amines, secondary amines and tertiary amines, also include cyclic amines and amines containing substituents, such as naturally occurring and synthetic amines containing substituents. Other pharmaceutically acceptable non-toxic organic bases capable of forming salts include ion exchange resins and arginine, betaine, caffeine, choline, N', N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, reduced glucosamine, glucosamine, histidine, isopropylamine, lysine, methylglucosamine, morpholine, piperazine, piperidine, polyamine resins, procaine, chloroprocaine, purine, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.

[0111] When compound provided by the invention is alkali, can be from pharmaceutically acceptable nontoxic acid, including inorganic acid and organic acid, conveniently make its corresponding salt.Such acid includes, as, acetic acid, benzenesulfonic acid, benzoic acid, camphorsulfonic acid, citric acid, ethanesulfonic acid, formic acid, fumaric acid, gluconic acid, glutamic acid, hydrobromic acid, hydrochloric acid, isethionic acid, lactic acid, maleic acid, malic acid, mandelic acid, methanesulfonic acid, mucic acid, nitric acid, embroic acid, pantothenic acid, phosphoric acid, succinic acid, sulfuric acid, oxalic acid, propionic acid, glycolic acid, hydroiodic acid, perchloric acid, cyclamic acid, salicylic acid, 2-naphthalenesulfonic acid, saccharinic acid, trifluoroacetic acid, tartaric acid and p-toluenesulfonic acid etc.Preferably, citric acid, hydrobromic acid, formic acid, hydrochloric acid, maleic acid, phosphoric acid, sulfuric acid and tartaric acid.More preferably, formic acid and hydrochloric acid.

[0112] Prodrugs of the compounds of the present invention are included within the scope of the present invention. Generally, the prodrug refers to a functional derivative that is easily converted into the desired compound in vivo. For example, any pharmaceutically acceptable salt, ester, salt of an ester or other derivative of the compounds of the present application, which can directly or indirectly provide the compounds of the present application or their pharmaceutically active metabolites or residues after administration to a receptor.

[0113] The compounds of the present invention may contain one or more asymmetric centers and may give rise to diastereomers and optical isomers. The present invention includes all possible diastereomers and racemic mixtures thereof, their substantially pure resolved enantiomers, all possible geometric isomers and pharmaceutically acceptable salts thereof.

[0114] When the compound represented by formula (I) exists in tautomerism, unless otherwise stated, the present invention includes any possible tautomerism and pharmaceutically acceptable salts thereof, and mixtures thereof.

[0115] The present invention also includes all isotopic atoms, whether in intermediates or final compounds. Isotopic atoms include atoms with the same atomic number, but different mass numbers. For example, isotopes of hydrogen include tritium and deuterium. All isotopic changes in the compounds of the present invention, whether radioactive or not, are included within the scope of the present invention.

[0116] The term "pharmaceutical composition" refers to a mixture of one or more compounds of the present application or pharmaceutically acceptable salts thereof and pharmaceutically acceptable excipients. The purpose of a pharmaceutical composition is to facilitate administration of the compounds of the present application to an organism.

[0117] In the present invention, "a", "an", "the", "at least one" and "one or more" are used interchangeably. Therefore, for example, a mixture comprising "a" pharmaceutically acceptable excipient composition can be interpreted as indicating that the pharmaceutical composition includes "one or more" pharmaceutically acceptable excipients.

[0118] The term "pharmaceutically acceptable excipients" refers to those excipients that have no significant irritation to the organism and do not impair the biological activity and performance of the active compound. Suitable excipients are well known to those skilled in the art, such as carbohydrates, waxes, water-soluble and / or water-swellable polymers, hydrophilic or hydrophobic materials, gelatin, oils, solvents, water, etc.

[0119] The pharmaceutical composition of the present invention can be prepared by combining the compound of the present application with suitable pharmaceutically acceptable excipients, for example, it can be formulated into solid, semi-solid, liquid or gaseous preparations, such as tablets, pills, capsules, powders, granules, ointments, emulsions, suspensions, suppositories, injections, inhalants, gels, microspheres and aerosols.

[0120] Typical routes of administration of the compounds of the invention or their pharmaceutically acceptable salts or their pharmaceutical compositions include, but are not limited to, oral, rectal, topical, inhalation, parenteral, sublingual, intravaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration.

[0121] The term "treat" generally refers to obtaining a desired pharmacological and / or physiological effect. The effect may be therapeutic in terms of partial or complete stabilization or cure of a disease and / or side effects resulting from a disease. As used herein, "treat" encompasses any treatment of a patient's disease that: (a) inhibits the symptoms of a disease, i.e., arrests its development; or (b) alleviates the symptoms of a disease, i.e., causes regression of the disease or symptoms.

[0122] The term "effective amount" means an amount of the compound of the present application that (i) treats or prevents a specific disease, condition, or disorder, (ii) alleviates, ameliorates, or eliminates one or more symptoms of a specific disease, condition, or disorder, or (iii) prevents or delays the onset of one or more symptoms of a specific disease, condition, or disorder described herein. The amount of the compound of the present application that constitutes a "therapeutically effective amount" varies depending on the compound, the disease state and its severity, the mode of administration, and the age of the mammal to be treated, but can be routinely determined by those skilled in the art based on their own knowledge and the present disclosure.

[0123] The administration routes of the compounds of the present invention or their pharmaceutically acceptable salts or their pharmaceutical compositions include, but are not limited to, oral, rectal, transmucosal, enteral administration, or topical, transdermal, inhalation, parenteral, sublingual, vaginal, intranasal, intraocular, intraperitoneal, intramuscular, subcutaneous, and intravenous administration. The preferred administration route is oral administration.

[0124] The N,N-diaryl urea derivatives of the present invention are NEK7 inhibitors and have AIM-2 agonist activity, and can be used to treat chronic inflammatory diseases such as gout, nephritis, atherosclerosis, non-alcoholic fatty hepatitis, hepatitis, diabetes, enteritis, acute inflammatory diseases such as traumatic brain injury, wounds, toothache, acute nephritis, viral infection, sepsis, burns, septic shock, cardiovascular diseases such as myocardial ischemia, heart failure, nervous system diseases such as Alzheimer's disease, Parkinson's disease, multiple sclerosis, meningitis, headache, neuropathic pain, autoimmune diseases such as rheumatoid arthritis, systemic vasculitis, respiratory system diseases such as COPD, asthma, pneumonia, tuberculosis, metabolic syndrome such as obesity, hyperglycemia, hypertension, dyslipidemia, hyperuricemia, hyperinsulinemia, digestive system diseases such as viral hepatitis, cirrhosis, liver fibrosis, enteritis, tumors and tumor metastasis, tumor complications; viral or bacterial infection, nerve damage or tumor. BRIEF DESCRIPTION OF THE DRAWINGS

[0125] Figure 1 The agonist activity of the series of compounds of the present invention on the AIM-2 inflammasome pathway at different concentrations. DETAILED DESCRIPTION

[0126] In order to make the above content clearer and more specific, the present invention will further illustrate the technical scheme of the present invention with the following examples. The following examples are only used to illustrate the specific embodiments of the present invention so that those skilled in the art can understand the present invention, but are not used to limit the scope of protection of the present invention. In the specific embodiments of the present invention, the technical means or methods not specifically described are conventional technical means or methods in the art.

[0127] Unless otherwise indicated, all temperatures herein are in degrees Celsius.

[0128] The present invention uses the following abbreviations:

[0129] Cs2CO3: cesium carbonate; DMF: N,N-dimethylformamide; TEA: triethylamine; Tol: toluene; AlCl3: aluminum chloride; DCM: dichloromethane; NH3H2O: ammonia water; EtOH: ethanol; AIBN: azobisisobutyronitrile; NBS: N-bromosuccinimide; DCE: 1,2-dichloroethane; DIPEA: N,N-diisopropylethylamine; H2: hydrogen; Pd / C: palladium on carbon; NaH: sodium hydride; THF: tetrahydrofuran; CbzCl: benzyl chloroformate; K2CO3: potassium carbonate; tBuONO: Tert-butyl nitrite; CuCN: cuprous cyanide; MeCN: acetonitrile; InCl3: indium chloride; CuI: cuprous iodide; DMSO: dimethyl sulfoxide; BH3: borane; SOCl2: dichlorothionyl; LDA: lithium diisopropylamide; Fe: iron powder; NH4Cl: ammonium chloride; STAB: sodium triacetoxyborohydride; SnCl2: stannous chloride; HCl: hydrogen chloride; TFA: trifluoroacetic acid; m-CPBA: m-chloroperbenzoic acid; NaOCH3: sodium methoxide; TfOH: trifluoromethanesulfonic acid; HBr: hydrogen bromide; AcOH: acetic acid.

[0130] The present invention also provides a method for preparing the above-mentioned compound, which is prepared by the following steps, including but not limited to the following method:

[0131] Route 1: (A) Synthesis route of series of compounds

[0132]

[0133] Among them, Cy and R 1 The definition of is as described in the general formula (II).

[0134] Compounds A-1 and A-2 are cyclized under alkaline conditions to generate intermediate A-3, intermediate A-3 is condensed with phenyl chloroformate to generate A-4, intermediate A-4 is condensed with intermediate M1 to form urea to obtain target compounds of the series (A)

[0135] Route 2: (B) Synthesis route of series compounds

[0136]

[0137] Among them, Cy and R 4a The definition of is as described in the general formula (II).

[0138] Compound B-1 reacts with 4-amino-6-chloropyrimidine-5-carbonitrile in alkaline to undergo nucleophilic substitution reaction to generate intermediate B-2, and intermediate B-2 and intermediate B-3 condense into urea to obtain target compounds of the (B) series.

[0139] Route 3: (C) Synthesis route of series compounds

[0140]

[0141] Among them, Cy and R 3 The definition of is as defined in the general formula (II).

[0142] Intermediate C-1 is coupled with 6-(4-amino-3-fluorophenoxy)-5-iodopyrimidin-4-amine under palladium catalysis to obtain intermediate C-2, and intermediate C-2 and intermediate C-3 are condensed into urea to obtain the target compound (C) series.

[0143] Route 4: (D) Synthesis route of series compounds

[0144]

[0145] Among them, ring A, ring B, ring C, R 1 , R 2 , n and m are as defined in the general formula (I).

[0146] The specific reaction process is as follows:

[0147] Aromatic amine compound Ia reacts with phenyl chloroformate to generate intermediate Ib; aromatic halide raw material Ic reacts with N-Boc to form aminophenol compound Id to generate aromatic ether compound Ie, and then acidification in a dichloromethane solution of trifluoroacetic acid removes the Boc protecting group to obtain aromatic amine intermediate If; intermediate Ib and intermediate If undergo amine ester exchange under alkaline conditions to obtain (D) series target molecules.

[0148] Route 5: (F) Synthesis route of series compounds

[0149]

[0150] Among them, ring A, ring B, ring C, R 1 , R 2 , n and m are as defined in the general formula (I).

[0151] The specific reaction process is as follows:

[0152] The aforementioned intermediate If reacts with phenyl chloroformate to generate a carbamate intermediate Ig, which then undergoes an amine ester exchange with the intermediate Ia under alkaline conditions to obtain the target molecules of the (F) series.

[0153] Intermediate M1: Synthesis of 4-amino-6-(4-amino-3-fluorophenoxy)pyrimidine-5-carbonitrile (M1)

[0154]

[0155] Step 1: Synthesis of 4-amino-6-(4-amino-3-fluorophenoxy)pyrimidine-5-carbonitrile

[0156] 4-Amino-6-chloropyrimidine-5-carbonitrile (7.70 g, 50.00 mmol) was dissolved in DMF (20 mL), cesium carbonate (35.86 g, 110.00 mmol) and 4-amino-3-fluorophenol (7.62 g, 60.0 mmol) were added, and microwave reaction was carried out at 90 ° C for 2 h. After the reaction was completed, it was cooled to room temperature, quenched with water (60 mL), extracted with ethyl acetate (3 times, 30 mL each time), and the organic phases were combined, washed with water (3 times, 20 mL each time), and then washed once with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography, and the eluent was 0-30% ethyl acetate in petroleum ether to obtain 8.32 g of 4-amino-6-(4-amino-3-fluorophenoxy)pyrimidine-5-carbonitrile as a white solid with a yield of 67.6%.

[0157] ESI-MS: m / z = 246.0 [M+H] + .

[0158] Intermediate M3: Synthesis of 4-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)phenol (M3)

[0159]

[0160] Step 1: Synthesis of 3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-amine (M2)

[0161] Dissolve p-methoxyphenylhydrazine hydrochloride (1.74 g, 10.00 mmol) and pivaloyl acetonitrile (1.38 g, 11.00 mmol) in toluene (20 mL), add triethylamine (1.52 g, 15.00 mmol), and heat the system under reflux overnight. The solvent was dried, and the residue was separated by column chromatography, with the eluent being 10-50% ethyl acetate in petroleum ether solution, to obtain 2.35 g of 3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazole-5-amine as a light yellow solid, with a yield of 95.5%;

[0162] ESI-MS: m / z = 246.0 [M+H] + .

[0163] Step 2: Synthesis of 4-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)phenol (M3)

[0164] 3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-amine (245mg, 1.00mmol) was dissolved in anhydrous dichloromethane (10mL), anhydrous aluminum chloride (755mg, 5.00mmol) was added, the system was replaced with nitrogen, and the temperature was raised to 40°C for 4 hours. The reaction solution was cooled to room temperature and quenched with water, extracted with dichloromethane three times (3 times, 20mL each time), the organic phases were combined, washed once with saturated brine (50mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography, the eluent was 0-50% ethyl acetate in petroleum ether solution, and 4-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)phenol 155mg, the yield was 67.1%.

[0165] ESI-MS: m / z = 232.0 [M+H] + .

[0166] Intermediate M5: Synthesis of 3-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)phenol (M5)

[0167]

[0168] Step 1: Synthesis of 3-(tert-butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-amine (M4)

[0169] Referring to step 1 in intermediate M3, p-methoxyphenylhydrazine hydrochloride was replaced with m-methoxyphenylhydrazine hydrochloride to obtain the target compound 3-(tert-butyl)-1-(3-methoxyphenyl)-1H-pyrazole-5-amine.

[0170] ESI-MS: m / z = 246.0 [M+H] + .

[0171] Step 2: Synthesis of 3-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)phenol (M5)

[0172] Referring to step 2 in intermediate M3, M3 was replaced by M4 to obtain the target compound 3-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)phenol.

[0173] ESI-MS: m / z = 232.0 [M+H] + .

[0174] Intermediate M6: Synthesis of 4-amino-6-(4-amino-3-methylphenoxy)pyrimidine-5-carbonitrile (M6)

[0175]

[0176] Step 1: Synthesis of 4-amino-6-(4-amino-3-methylphenoxy)pyrimidine-5-carbonitrile

[0177] 4-Amino-6-chloropyrimidine-5-carbonitrile (7.70 g, 50.00 mmol) was dissolved in DMF (20 mL), cesium carbonate (35.86 g, 110.00 mmol) and 4-amino-3-methylphenol (7.38 g, 60.0 mmol) were added, and microwave reaction was performed at 90 ° C for 1 hour. After the reaction was completed, it was cooled to room temperature, quenched with water (60 mL), extracted with ethyl acetate (3 times, 30 mL each time), and the organic phases were combined, washed with water (3 times, 20 mL each time), and then washed once with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography, and the eluent was 0-30% ethyl acetate in petroleum ether to obtain 4-amino-6-(4-amino-3-methylphenoxy)pyrimidine-5-carbonitrile 8.01 g as a white solid with a yield of 66.5%.

[0178] ESI-MS: m / z = 242.0 [M+H] + .

[0179] Intermediate M7: Synthesis of 3-(tert-butyl)-1-(4-iodophenyl)-1H-pyrazol-5-amine (M7)

[0180]

[0181] Step 1: Synthesis of 3-(tert-butyl)-1-(4-iodophenyl)-1H-pyrazol-5-amine (M7)

[0182] Dissolve p-iodophenylhydrazine hydrochloride (2.70 g, 10.00 mmol) and pivaloyl acetonitrile (1.38 g, 11.00 mmol) in toluene (20 mL), add triethylamine (1.52 g, 15.00 mmol), and heat the system under reflux overnight. The solvent was dried, and the residue was separated by column chromatography, with the eluent being 10-50% ethyl acetate in petroleum ether solution, to obtain 3.12 g of 3-(tert-butyl)-1-(4-iodophenyl)-1H-pyrazole-5-amine as a light yellow solid, with a yield of 91.2%;

[0183] ESI-MS: m / z = 342.0 [M+H] + .

[0184] Intermediate M8: Synthesis of 6-(4-amino-3-fluorophenoxy)-5-iodopyrimidin-4-amine (M8)

[0185]

[0186] Step 1: Synthesis of 6-chloro-5-iodopyrimidin-4-amine

[0187] Dissolve 4,6-dichloro-5-iodopyrimidine (540 mg, 2.00 mmol) in ethanol (10 mL), slowly add ammonia water (0.5 mL), and stir at room temperature overnight. After the reaction, concentrate under reduced pressure to obtain 502 mg of 6-chloro-5-iodopyrimidine-4-amine as a yellow solid with a yield of 98.0%.

[0188] ESI-MS: m / z = 256.0 [M + H] + .

[0189] Step 2: Synthesis of 6-(4-amino-3-fluorophenoxy)-5-iodopyrimidin-4-amine (M8)

[0190] 6-Chloro-5-iodopyrimidin-4-amine (500 mg, 1.96 mmol) and 4-amino-3-fluorophenol (299 mg, 2.35 mmol) were dissolved in DMF (5 mL), cesium carbonate (1.28 g, 3.92 mmol) was added, and the system was subjected to microwave reaction at 100 ° C for 1 hour. Cool to room temperature, add water to quench, extract with ethyl acetate three times (3 times, 20 mL each time), combine the organic phases, wash the organic phase with water once (20 mL), wash with saturated brine (50 mL), dry with anhydrous sodium sulfate, and filter. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography, the eluent was 0-30% ethyl acetate in petroleum ether solution, and 6-(4-amino-3-fluorophenoxy)-5-iodopyrimidin-4-amine 287 mg was obtained as a yellow solid with a yield of 42.3%;

[0191] ESI-MS: m / z = 347.0 [M+H] + .

[0192] Intermediate Ia-1: Synthesis of 3-(tert-butyl)-1-phenyl 1H-pyrazole-5-amine (Ia-1)

[0193]

[0194] Step 1: Synthesis of 3-(tert-butyl)-1-phenyl 1H-pyrazole-5-amine (Ia-1)

[0195] Dissolve phenylhydrazine (8.3 mL, 84 mmol) and pivaloyl acetonitrile (10 g, 80 mmol) in toluene (40 mL), and heat the system under reflux overnight. The solvent is dried and the residue is separated by column chromatography with a 30% ethyl acetate in petroleum ether solution as the eluent to obtain a light yellow solid (13.2 g, yield 77%).

[0196] ESI-MS: m / z = 216.0 [M+H] + .

[0197] Intermediates Ia-2 to Ia-5: 3-tert-butyl-1-(4-methoxyphenyl)-1H-pyrazol-5-amine (Ia-2), 3-tert-butyl-1-(4-pyridyl)-1H-pyrazol-5-amine (Ia-3), 3-tert-butyl-1-(4-cyanophenyl)-1H-pyrazol-5-amine (Ia-4) and 3-tert-butyl-1-(4-fluorophenyl)-1H-pyrazol-5-amine (Ia-5)

[0198] The preparation methods of intermediates 1a-2 to 1a-5 are similar to those of intermediate 1a-1, except that phenylhydrazine is replaced with the corresponding arylhydrazine to obtain the target intermediates as shown in the following table:

[0199]

[0200]

[0201] Intermediates Ia-6 to Ia-7: Synthesis of 1-phenyl-3-(trifluoromethyl)-1H-pyrazol-5-amine (Ia-6) and 2-(5-amino-1-phenyl-1H-pyrazol-3-yl)propyl-2-ol (Ia-7)

[0202] The preparation methods of intermediates Ia-6 to Ia-7 are similar to those of intermediate Ia-1, except that pivaloyl acetonitrile is replaced with the corresponding acyl acetonitrile to obtain the target intermediates as shown in the following table:

[0203]

[0204] Intermediate Ia-8: Synthesis of 4-morpholinomethyl-3-trifluoromethylaniline (Ia-8)

[0205]

[0206] Step 1: Synthesis of 1-(bromomethyl)-4-nitro-2-trifluoromethylbenzene

[0207] N-bromosuccinimide (430 mg, 2.42 mmol) was added to a solution of 1-methyl-4-nitro-2-trifluoromethylbenzene (500 mg, 2.44 mmol) and AIBN (40 mg, 0.24 mmol) in dichloroethane (10 mL) at room temperature, and the mixture was refluxed for 18 hours. The reaction solution was concentrated and extracted with water and ethyl acetate, and the organic phases were combined, washed with water and saturated brine once each, dried over anhydrous sodium sulfate, and concentrated to obtain 510 mg of an oily substance, which was used directly in the next step without purification.

[0208] ESI-MS: m / z = 284.0, 296.0 [M+H] + .

[0209] 1H NMR (400MHz, DMSO-d6): δ8.56 (dd, J1=8.4Hz, J1=2.4Hz, 1H), 8.44 (d, J=2.4Hz, 1H), 8.06 (d, J=8.8Hz, 1H), 4.90 (s, 2H).

[0210] Step 2: Synthesis of 4-(4-nitro-2-trifluoromethylphenyl)morpholine

[0211] The oil obtained in step 1 was dissolved in dichloromethane (10 mL), and N,N-diisopropylethylamine (0.64 mL, 3.66 mmol) and morpholine (0.25 mL, 2.93 mmol) were added in sequence, and the mixture was stirred at room temperature overnight. Water was added, and the mixture was extracted with dichloromethane. The organic phases were combined, washed once with saturated brine, and dried over anhydrous sodium sulfate. After concentration, the residue was separated by column chromatography to obtain 573 mg of the product, with a two-step yield of 81.0%.

[0212] ESI-MS: m / z = 291.0 [M+H] + .

[0213] Step 3: Synthesis of 4-morpholinomethyl-3-trifluoromethylaniline (Ia-8)

[0214] 4-(4-nitro-2-trifluoromethylphenyl)morpholine (570 mg, 1.97 mmol) was added to ethanol (10 mL), and 10% Pd / C (50 mg) was added. The system was replaced with hydrogen and reacted at 60°C for 6 h. Cooled to room temperature, filtered through diatomaceous earth, the filter cake was washed with a small amount of ethanol, and the filtrate was combined and dried to obtain 466 mg of product, with a two-step yield of 91.2%.

[0215] ESI-MS: m / z = 261.0 [M+H] + .

[0216] Intermediate Ia-9: Synthesis of 4-((4-methylpiperazin-1-yl)methyl)-3-(trifluoromethyl)aniline (Ia-9)

[0217]

[0218] Intermediate Ia-9 was prepared similarly to Intermediate Ia-8, except that morpholine was replaced by N-methylpiperazine.

[0219] ESI-MS: m / z = 274.0 [M+H] + .

[0220] Intermediate Ia-10: Synthesis of 6-(morpholinomethyl)-5-(trifluoromethyl)pyridin-3-amine (Ia-10)

[0221]

[0222] The preparation method of intermediate Ia-10 is similar to that of intermediate Ia-8, except that 1-methyl-4-nitro-2-trifluoromethylbenzene is replaced by 2-methyl-5-nitro-3-(trifluoromethyl)pyridine;

[0223] ESI-MS: m / z = 262.0 [M+H] + .

[0224] Intermediate Ia-11: Synthesis of 4-((1-methylpiperidin-4-yl)oxy)-3-(trifluoromethyl)aniline (Ia-11)

[0225]

[0226] Step 1: Synthesis of 1-methyl-4-(4-nitro-2-(trifluoromethyl)phenoxy)piperidine

[0227] Dissolve 1-methylpiperidin-4-ol (276 mg, 2.4 mmol) in 5 mL of ultra-dry DMF, slowly add sodium hydride (160 mg, 4.0 mmol) under ice bath, slowly add 2-fluoro-5-nitrotrifluorotoluene (418 mg, 2.0 mmol) in DMF (2 mL) solution to the system after stirring for 1 hour, and heat the reaction solution to room temperature for 6 hours. After the reaction solution is concentrated, extract with water and ethyl acetate, combine the organic phases, wash with water and saturated brine once, dry with anhydrous sodium sulfate and concentrate to obtain 643 mg of oil, which is directly used in the next step.

[0228] ESI-MS: m / z = 305.0 [M+H] + .

[0229] Step 2: Synthesis of 4-((1-methylpiperidin-4-yl)oxy)-3-(trifluoromethyl)aniline (Ia-11)

[0230] The oil obtained in the previous step was dissolved in ethanol (10 mL), and 60 mg of 10% Pd / C was added in sequence. The system was replaced with hydrogen and reacted at 60°C for 6 h. Cooled to room temperature, filtered with diatomaceous earth, the filter cake was washed with a small amount of ethanol, the filtrate was combined, and the residue was separated by column chromatography after being dried by spin drying to obtain 404 mg of the target intermediate Ia-11, with a two-step yield of 73.7%.

[0231] ESI-MS: m / z = 275.0 [M + H] + .

[0232] Intermediates Ia-12 to Ia-15: Synthesis of 5-amino-2-((1-methylpiperidin-4-yl)oxy)benzonitrile (Ia-12), 6-amino-2-((1-methylpiperidin-4-yl)oxy)-5-(trifluoromethyl)pyridin-3-amine (Ia-13), 4-morpholinyl-3-trifluoromethylaniline (Ia-14) and 4-(4-methylpiperazin-1-yl)-3-trifluoromethylaniline (Ia-15)

[0233] The preparation method of intermediates Ia-12 to Ia-15 is similar to that of intermediate Ia-11, except that 1-methylpiperidin-4-ol is replaced by a corresponding nucleophilic reagent or 2-fluoro-5-nitrotrifluorotoluene is replaced by a corresponding halogenated aromatic heterocycle to obtain the target intermediates as shown in the following table:

[0234]

[0235]

[0236] Intermediate Ib-1: Synthesis of phenyl (3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) carbamate (Ib-1)

[0237]

[0238] Step 1: Synthesis of phenyl (3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) carbamate (Ib-1)

[0239] The intermediate Ia-1 (3.55 g, 16.49 mmol) was dissolved in tetrahydrofuran (20 mL), triethylamine (1.84 g, 18.14 mmol) was added, the system was replaced with nitrogen, and a tetrahydrofuran solution of phenyl chloroformate (2.58 g, 16.49 mmol) was added dropwise under an ice bath, and the reaction solution was stirred at room temperature for 1 hour. Water (10 mL) was added to the system, and extracted with ethyl acetate (3 times, 20 mL each time), the organic phases were combined, dried over anhydrous sodium sulfate, and spin-dried, and the residue was separated by column chromatography, the eluent was 0-9% ethyl acetate in petroleum ether, and 2.0 g of white solid was obtained, with a yield of 36.2%.

[0240] ESI-MS: m / z = 336.0 [M+H] + .

[0241] Intermediates Ic-1~Ic-5, Ic-8, Ic-13

[0242] Intermediates Ic-1 to Ic-5, Ic-8 and Ic-13 are all commercially available and have the following structures:

[0243]

[0244] Intermediate Ic-6: Synthesis of 4-amino-6-chloro-2-(methylthio)pyrimidine-5-carbonitrile (Ic-6)

[0245]

[0246] Step 1: Synthesis of 4-amino-6-chloro-2-(methylthio)pyrimidine-5-carbonitrile (Ic-6)

[0247] 4,6-dichloro-2-(methylthio)pyrimidine-5-carbonitrile (1.10 g, 5.0 mmol) was dissolved in tetrahydrofuran (10 mL), 30% aqueous ammonia (623 μL, 11.0 mmol) was added, and the mixture was stirred at room temperature for 2 h. The reaction solution was dried by rotary evaporation, and the residue was extracted with water and ethyl acetate. The organic layers were combined and dried over anhydrous sodium sulfate to obtain 975 mg of the target intermediate as a white solid with a yield of 97.5%.

[0248] ESI-MS: m / z = 201.0 [M+H] + .

[0249] Intermediate Ic-7: Synthesis of 8-bromo-4-(4-methoxybenzyl)-2H-pyrido[3,2-b][1,4]oxazin-3-(4H)-one (Ic-7)

[0250]

[0251] Step 1: Synthesis of 2-amino-3-hydroxy-4-bromopyridine

[0252] Dissolve 2-amino-2-hydroxypyridine (5.00 g, 45.41 mmol) in anhydrous ethanol (50 mL), add liquid bromine (7.26 g, 45.41 mmol) dropwise under ice bath, and stir the mixture at room temperature for three days. Remove the solvent by vacuum rotary evaporation, add saturated hydrogen chloride ethyl acetate solution (50 mL) to the concentrate, stir at room temperature for 1 h, and a large amount of solid precipitates. Filter under reduced pressure, wash the filter cake three times with ethyl acetate (3 times, 10 mL each time). Collect the filter cake, and after drying, obtain 4.60 g of crude product as a brown solid.

[0253] ESI-MS: m / z=189.0,191.0[M+H] + .

[0254] 1 H NMR (400MHz, DMSO-d6): δ8.06(s,2H),7.24(d,J=6.8Hz,1H),7.27(s,1H),7.14(s,1H),7.05(d,J=6.8Hz,1H),7.01(s,1H).

[0255] Step 2: Synthesis of 8-bromo-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one

[0256] Dissolve 2-amino-3-hydroxy-4-bromopyridine (400 mg, 0.53 mmol) in N,N-dimethylformamide (10 mL), add potassium carbonate (161 mg, 1.16 mmol) and stir at room temperature for 15 minutes. Add chloroacetyl chloride (66 mg, 0.58 mmol) dropwise under an ice bath. After the dropwise addition, stir at room temperature for 1 hour. Heat to 80 ° C and stir for 1 hour. After the mixture is cooled to room temperature, add water to quench, filter and extract three times with ethyl acetate (3 times, 20 mL each time), wash the combined organic phase with water three times (3 times, 20 mL each time), wash with saturated brine (50 mL), dry over anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure. 120 mg of the target product (crude product) is obtained as a brown oil.

[0257] ESI-MS: m / z = 229.0, 231.0 [M+H] + .

[0258] Step 3: Synthesis of 8-bromo-4-(4-methoxybenzyl)-2H-pyrido[3,2-b][1,4]oxazin-3-(4H)-one (Ic-7)

[0259] 8-Bromo-2H-pyrido[3,2-b][1,4]oxazine-3(4H)-one (120 mg, 0.52 mmol) was dissolved in N,N-dimethylformamide (3 mL), cesium carbonate (256 mg, 0.79 mmol) was added, and p-methoxybenzyl chloride (98 mg, 0.63 mmol) was added dropwise after stirring at room temperature for 15 minutes. The reaction solution was stirred at room temperature for 1 hour. The mixture was quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), the combined organic phase was washed with water three times (3 times, 20 mL each time), washed with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was purified by preparative thin layer chromatography with a developing solvent of 30% ethyl acetate in petroleum ether to obtain 140 mg of the target intermediate Ic-7 as a pink solid with a yield of 82.0%.

[0260] ESI-MS: m / z=349.0,351.0[M+H] + .

[0261] 1 H NMR (400MHz, DMSO-d6): δ7.87(d,J=5.2Hz,1H),7.36(d,J=5.2Hz,1H),7.26 (d,J=8.8Hz,2H),6.85-6.83(m,2H),5.15(s,2H),4.96(s,2H),3.70(s,3H).

[0262] Intermediate Ic-9: Synthesis of (5-bromothiazol-2-yl)carbamic acid benzyl (Ic-9) ester

[0263]

[0264] Step 1: Synthesis of benzyl (Ic-9) (5-bromothiazol-2-yl)carbamate

[0265] Dissolve 2-amino-5-bromothiazole (1.78 g, 10.0 mmol) in ultra-dry tetrahydrofuran (20 mL), add potassium carbonate (3.45 g, 25.0 mmol), slowly drop benzyl chloroformate (2.11 g, 12.0 mmol) into the system, stir at room temperature and react overnight. The reaction solution was spin-dried, the residue was extracted with water and ethyl acetate, the organic layers were combined and dried over anhydrous sodium sulfate to obtain 2.76 g of the target intermediate as a white solid, with a yield of 88.5%.

[0266] ESI-MS: m / z = 313.0, 315.0 [M+H] + .

[0267] 1 H NMR (400MHz, DMSO-d6): δ12.14(s,1H),7.47(s,1H),7.44-7.34(m,5H),5.24(s,1H).

[0268] Intermediate Ic-10: Synthesis of 5-bromothiazole-2-carbonitrile (Ic-10)

[0269]

[0270] Step 1: Synthesis of 5-bromothiazole-2-carbonitrile (Ic-10)

[0271] Tert-butyl nitrite (361 mg, 3.5 mmol) and cuprous cyanide (313 mg, 3.5 mmol) were dissolved in acetonitrile (15 mL). The system was replaced with nitrogen and heated to 70 ° C for 2 h. A solution of 2-amino-5-bromothiazole (311 mg, 1.75 mmol) in acetonitrile (7 mL) was added dropwise and the reaction was continued at 70 ° C for 2 h. The mixture was filtered through diatomaceous earth, the filtrate was dried by rotary evaporation, and the residue was separated and purified by column chromatography, the eluent was 0-10% ethyl acetate in petroleum ether solution, and 92 mg of the target product was obtained as a yellow oil with a yield of 28.0%;

[0272] ESI-MS: m / z=189.0,191.0[M+H] + .

[0273] Intermediates Ic-11 and Ic-12: Synthesis of benzyl (5-bromo-1,3,4-thiadiazol-2-yl) carbamate (Ic-11) and benzyl (5-bromooxazol-2-yl) carbamate (Ic-12)

[0274] The preparation methods of intermediates Ic-11 and Ic-12 are similar to those of intermediate Ic-9, except that 2-amino-5-bromothiazole is replaced by 2-amino-5-bromo-1,3,4-thiadiazole and 2-amino-5-bromooxazole to obtain the target intermediates as shown in the following table:

[0275]

[0276] Intermediate Id-1: Synthesis of tert-butyl (2-fluoro-4-hydroxyphenyl)carbamate (Id-1)

[0277]

[0278] Step 1: Synthesis of tert-butyl (2-fluoro-4-hydroxyphenyl)carbamate (Id-1)

[0279] Dissolve 4-amino-3-fluorophenol (3.0 g, 23.60 mmol) in 20 mL of dichloromethane, add indium chloride (52 mg, 0.24 mmol) and di-tert-butyl dicarbonate (5.67 g, 25.96 mmol), heat to 40°C and stir for 2 hours. The solvent was dried and the residue was separated by column chromatography with an eluent of 0-18% ethyl acetate: petroleum ether to obtain 4.9 g of yellow liquid with a yield of 91.4%.

[0280] ESI-MS: m / z = 228.0 [M+H] + .

[0281] Intermediates Id-2 to Id-10: Synthesis of tert-butyl (2-chloro-4-hydroxyphenyl)carbamate (Id-2), tert-butyl (2-methyl-4-hydroxyphenyl)carbamate (Id-3), tert-butyl (4-hydroxyphenyl)carbamate (Id-4), tert-butyl (2-difluoromethyl-4-hydroxyphenyl)carbamate (Id-5), tert-butyl (2,6-difluoro-4-hydroxyphenyl)carbamate (Id-6), tert-butyl (3-fluoro-4-hydroxyphenyl)carbamate (Id-7), tert-butyl (2,5-difluoro-4-hydroxyphenyl)carbamate (Id-8), tert-butyl (5-hydroxypyridin-2-yl)carbamate (Id-9), and tert-butyl (3-fluoro-5-hydroxypyridin-2-yl)carbamate (Id-10)

[0282] The preparation methods of intermediates Id-2 to Id-10 are similar to those of intermediate Id-1, except that 4-amino-3-fluorophenol is replaced with the corresponding phenol raw material or hydroxypyridine raw material to obtain the target intermediates as shown in the following table:

[0283]

[0284]

[0285] Example 1 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)urea (Compound 1)

[0286]

[0287] Step 1: Synthesis of 3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-amine

[0288] 3-(tert-butyl)-1-(4-iodophenyl)-1H-pyrazole-5-amine (350 mg, 1.03 mmol) was dissolved in dimethyl sulfoxide (5 mL), and dimethylamine hydrochloride (418 mg, 5.13 mmol), cesium carbonate (668 mg, 2.05 mmol), cuprous iodide (20 mg, 0.10 mmol) and L-proline (24 mg, 0.21 mmol) were added, and the system was microwaved at 100 ° C for 1 h. After the reaction solution was cooled to room temperature, it was quenched with water and extracted with ethyl acetate three times (3 times, 20 mL each time), the organic phases were combined, the organic phases were washed with water three times (3 times, 20 mL each time), washed once with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with 0-30% ethyl acetate in petroleum ether as the eluent to give 155 mg of 3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-amine in a yield of 58.5%.

[0289] ESI-MS: m / z = 259.0 [M+H] + .

[0290] Step 2: Synthesis of phenyl (3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)carbamate

[0291] 3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-amine (155mg, 0.60mmol) was dissolved in dichloromethane (5mL), triethylamine (91mg, 0.90mmol) was added, phenyl chloroformate (112mg, 0.72mmol) was added dropwise under ice bath, and the temperature was maintained for 4 hours. The reaction solution was quenched with water, extracted with dichloromethane three times (3 times, 20mL each time), the organic phases were combined, washed once with saturated brine (20mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain phenyl (3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl) carbamate 90mg, with a yield of 39.7%.

[0292] ESI-MS: m / z = 379.0 [M+H] + .

[0293] Step 3: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)urea

[0294] Phenyl (3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)carbamate (90 mg, 0.24 mmol), 4-amino-6-(4-amino-3-fluorophenoxy)pyrimidine-5-carbonitrile (59 mg, 0.24 mmol) and triethylamine (24 mg, 0.24 mmol) were dissolved in tetrahydrofuran (5 mL), and the temperature was raised to 70 ° C for 4 hours. The system was cooled to room temperature, quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), and the organic phases were combined, washed with water once (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with 0-3% methanol in dichloromethane as the eluent to give 30 mg of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)urea in a yield of 23.8%.

[0295] ESI-MS: m / z = 530.0 [M + H] + .

[0296] 1H NMR (400MHz, DMSO-d6): δ9.01(d,J=2.4Hz,1H),8.70(s,1H),8.19(s,1H),8.16(t,J=9.2Hz,1H),7.94(s,2H),7.30-7.2 5(m,3H),7.04(dt,J1=8.8Hz,J2=1.6Hz,1H),6.85(dd,J1=6.8Hz,J2=2.0Hz,2H),6.34(s,1H),2.96(s,6H),1.26(s,9H).

[0297] Example 2 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-5-yl)urea (Compound 2)

[0298]

[0299] Step 1: Synthesis of 3-(tert-butyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-5-amine

[0300] Dissolve 4-trifluoromethoxyphenylhydrazine hydrochloride (228 mg, 1.00 mmol) and pivaloyl acetonitrile (138 mg, 1.10 mmol) in toluene (4 mL), add triethylamine (151 mg, 1.50 mmol), and heat the system under reflux overnight. The solvent was dried, and the residue was separated by column chromatography, with the eluent being 10-50% ethyl acetate in petroleum ether solution, to obtain 274 mg of 3-(tert-butyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazole-5-amine, with a yield of 91.6%;

[0301] ESI-MS: m / z = 300.0 [M + H] + .

[0302] Step 2: Synthesis of phenyl (3-(tert-butyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-5-yl)carbamate

[0303] 3-(tert-butyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-5-amine (274mg, 0.92mmol) was dissolved in dichloromethane (5mL), triethylamine (139mg, 1.37mmol) was added, phenyl chloroformate (171mg, 1.10mmol) was added dropwise under ice bath, and the temperature was maintained for 4 hours. The reaction solution was quenched with water, extracted with dichloromethane three times (3 times, 20mL each time), the organic phases were combined, washed once with saturated brine (20mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 110mg of phenyl (3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)carbamate, with a yield of 28.6%.

[0304] ESI-MS: m / z = 420.0 [M + H] + .

[0305] Step 3: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-5-yl)urea

[0306] Phenyl (3-(tert-butyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-5-yl)carbamate (110 mg, 0.26 mmol), 4-amino-6-(4-amino-3-fluorophenoxy)pyrimidine-5-carbonitrile (64 mg, 0.26 mmol) and triethylamine (27 mg, 0.26 mmol) were dissolved in tetrahydrofuran (5 mL), and the temperature was raised to 70 ° C for 4 hours. The system was cooled to room temperature, quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), and the organic phases were combined, washed with water once (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with 0-3% methanol in dichloromethane as the eluent to give 45 mg of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(trifluoromethoxy)phenyl)-1H-pyrazol-5-yl)urea in a yield of 30.3%.

[0307] ESI-MS: m / z = 571.0 [M+H] + .

[0308] 1H NMR (400MHz, DMSO-d6): δ8.93(s,1H),8.91(s,1H),8.19(s,1H),8.08(t,J=6.0Hz,1H),7.68-7.66(m,2H) ,7.55(d,J=5.6Hz,2H),7.31(dd,J1=8.0Hz,J2=2.0Hz,1H),7.04-7.02(m,1H),6.42(s,1H),1.28(s,9H).

[0309] Example 3 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(methylthio)phenyl)-1H-pyrazol-5-yl)urea (Compound 3)

[0310]

[0311] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with 4-(methylthio)phenylhydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(methylthio)phenyl)-1H-pyrazol-5-yl)urea.

[0312] ESI-MS: m / z = 533.0 [M+H] + .

[0313] 1 H NMR (400MHz, DMSO-d6): δ8.96(s,1H),8.82(s,1H),8.19(s,1H),8.12(t,J=6.0Hz,1H),7.46-7.45(m,2H),7.4 2-7.41(m,2H),7.30(dd,J1=7.6Hz,J2=2.0Hz,1H),7.04-7.02(m,1H),6.39(s,1H),2.53(s,3H),1.27(s,9H).

[0314] Example 4 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 4)

[0315]

[0316] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with 3-methoxyphenylhydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0317] ESI-MS: m / z = 517.0 [M+H] + .

[0318] 1 H NMR (400MHz, DMSO-d6): δ9.03(s,1H),8.88(s,1H),8.19(s,1H),8.11(t,J=9.2Hz,1H),7.47(t,J=8.0Hz,1H),7. 30(dd,J1=11.6Hz,J2=2.8Hz,1H),7.11-7.07(m,2H),7.04-6.98(m,2H),6.40(s,1H),3.81(s,3H),1.28(s,9H).

[0319] Example 5 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)urea (Compound 5)

[0320]

[0321] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with 3-trifluoromethylphenylhydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-(trifluoromethyl)phenyl)-1H-pyrazol-5-yl)urea.

[0322] ESI-MS: m / z = 555.0 [M+H] + .

[0323] 1 H NMR (400MHz, DMSO-d6): δ8.92(s,1H),8.89(s,1H),8.18(s,1H),8.00(t,J=6.0Hz,1H),7.89-7.87(m,2H),7.78 -7.77(m,2H),7.30(dd,J1=7.6Hz,J2=2.0Hz,1H),7.03(dt,J1=6.0Hz,J2=1.2Hz,1H),6.43(s,1H),1.29(s,9H).

[0324] Example 6 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-fluorophenyl)-1H-pyrazol-5-yl)urea (Compound 6)

[0325]

[0326] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with 3-fluorophenylhydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-fluorophenyl)-1H-pyrazol-5-yl)urea.

[0327] ESI-MS: m / z = 505.0 [M+H] + .

[0328] 1 H NMR (400MHz, DMSO-d6): δ8.96(s,1H),8.88(s,1H),8.19(s,1H),8.07(t,J=6.0Hz,1H),7.60(q,J=5.2Hz, 1H),7.44-7.41(m,2H),7.31-7.26(m,2H),7.04(dt,J1=6.0Hz,J2=1.2Hz,1H),6.42(s,1H),1.28(s,9H).

[0329] Example 7 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-cyanophenyl)-1H-pyrazol-5-yl)urea (Compound 7)

[0330]

[0331] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with 3-cyanophenylhydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-cyanophenyl)-1H-pyrazol-5-yl)urea.

[0332] ESI-MS: m / z = 512.0 [M+H] + .

[0333] 1H NMR (400MHz, DMSO-d6): δ8.99(s,2H),8.19(s,1H),8.04(t,J=1.2Hz,1H),8.02(t,J=6.0Hz,1H),7.92-7.90(m,1H),7.88-7.86(dt ,J1=5.2Hz, J2=0.8Hz,1H),7.75(t,J=5.2Hz,1H),7.31(dd,J1=8.0Hz,J2=2.0Hz,1H),7.04-7.01(m,1H),6.43(s,1H),1.29(s,9H).

[0334] Example 8 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 8)

[0335]

[0336] Step 1: Synthesis of 3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-amine

[0337] Dissolve 4-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)phenol (100 mg, 0.43 mmol) in DMF (5 mL), add potassium carbonate (119 mg, 0.87 mmol) and iodoethane (81 mg, 5.00 mmol), and stir the system at room temperature overnight. Add saturated ammonium chloride solution (20 mL) to quench, extract with ethyl acetate three times (3 times, 20 mL each time), combine the organic phases, wash the organic phase with water (3 times, 20 mL each time), wash once with saturated brine (50 mL), dry with anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure. The residue is purified by column chromatography, the eluent is 0-30% ethyl acetate in petroleum ether solution, and 104 mg of 3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-amine is obtained, and the yield is 92.8%.

[0338] ESI-MS: m / z = 260.0 [M + H] + .

[0339] Step 2: Synthesis of phenyl (3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl)carbamate

[0340] 3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazole-5-amine (100 mg, 0.39 mmol) was dissolved in dichloromethane (5 mL), triethylamine (56 mg, 0.56 mmol) was added, phenyl chloroformate (72 mg, 0.46 mmol) was added dropwise under ice bath, and the temperature was maintained for 4 hours. The reaction solution was quenched with water, extracted with dichloromethane three times (3 times, 20 mL each time), the organic phases were combined, washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 40 mg of phenyl (3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazole-5-yl) carbamate, with a yield of 27.3%.

[0341] ESI-MS: m / z = 380.0 [M+H] + .

[0342] Step 3: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl)urea

[0343] Phenyl (3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)carbamate (40 mg, 0.11 mmol), 4-amino-6-(4-amino-3-fluorophenoxy)pyrimidine-5-carbonitrile (27 mg, 0.11 mmol) and triethylamine (16 mg, 0.16 mmol) were dissolved in tetrahydrofuran (5 mL), and the temperature was raised to 70 ° C for 4 hours. The system was cooled to room temperature, quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), and the organic phases were combined, washed with water once (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with 0-3% methanol in dichloromethane as the eluent to give 12 mg of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl)urea in a yield of 21.4%.

[0344] ESI-MS: m / z = 531.0 [M+H] + .

[0345] 1H NMR (400MHz, DMSO-d6): δ8.97(d,J=2.4Hz,1H),8.76(s,1H),8.19(s,1H),8.11(t,J=9.2Hz,1H),7.41-7.37(m,2H),7.30(dd,J1=12 .0Hz,J2=2.8Hz,1H),7.09-7.05(m,2H),7.04-7.00(m,1H),6.36(s,1H),4.12(q,J=6.8Hz,2H),1.38(t,J=6.8Hz,3H),1.26(s,9H).

[0346] Example 9 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-propoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 9)

[0347]

[0348] Referring to steps 1 to 3 in Example 8, iodoethane was replaced with 1-iodopropane to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-propoxyphenyl)-1H-pyrazol-5-yl)urea.

[0349] ESI-MS: m / z = 545.0 [M + H] + .

[0350] 1 H NMR (400MHz, DMSO-d6): δ8.99(d,J=2.4Hz,1H),8.77(s,1H),8.19(s,1H),8.13(t,J=8.8Hz,1H),7.97(s,2H),7.41-7.36(m,2H),7.30(dd,J1=12.0Hz ,J2=2.8Hz,1H),7.10-7.04(m,2H),7.04-7.00(m,1H),6.36(s,1H),4.00( t,J=6.4Hz,2H),1.79(q,J=6.8Hz,2H),1.26(s,9H),1.01(t,J=7.2Hz,3H).

[0351] Example 10 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-isopropoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 10)

[0352]

[0353] Referring to steps 1 to 3 in Example 8, iodoethane was replaced with 2-iodopropane to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-isopropoxyphenyl)-1H-pyrazol-5-yl)urea.

[0354] ESI-MS: m / z = 545.0 [M + H] + .

[0355] 1 H NMR (400MHz, DMSO-d6): δ8.97(s,1H),8.76(s,1H),8.19(s,1H),8.13(t,J=9.2Hz,1H),7.39(d,J=8.8Hz,3H),7.30(d d,J1=12.0Hz, J2=2.8Hz,1H),7.07-7.01(m,4H),6.36(s,1H),4.71-4.65(m,1H),1.30(d,J=6.0Hz,6H),1.26(s,9H).

[0356] Example 11 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-1H-pyrazol-5-yl)urea (Compound 11)

[0357]

[0358] Referring to steps 1 to 3 in Example 8, iodoethane was replaced with 2-bromo-N,N-dimethylethan-1-amine to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(2-(dimethylamino)ethoxy)phenyl)-1H-pyrazol-5-yl)urea.

[0359] ESI-MS: m / z = 574.0 [M+H] + .

[0360] 1H NMR (400MHz, DMSO-d6): δ8.99 (d, J = 2.4Hz, 1H), 8.79 (s, 1H), 8.19 (s, 1H), 8. 13(t,J=9.2Hz,1H),7.98(s,2H),7.41-7.39(m,2H),7.30(dd,J1=11.6Hz,J2 =2.8Hz,1H),7.11-7.08(m,2H),7.04(dt,J1=8.8Hz,J2=1.6Hz,1H),6.36(s, 1H),4.14(t,J=5.6Hz,2H),2.70(t,J=5.6Hz,2H),2.25(s,6H),1.27(s,9H).

[0361] Example 12 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(cyclobutylmethoxy)phenyl)-1H-pyrazol-5-yl)urea (Compound 12)

[0362]

[0363] Referring to steps 1 to 3 in Example 8, iodoethane was replaced with bromomethylcyclobutane to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(cyclobutylmethoxy)phenyl)-1H-pyrazol-5-yl)urea.

[0364] ESI-MS: m / z = 571.0 [M+H] + .

[0365] 1 H NMR (400MHz, DMSO-d6): δ8.97-8.96(m,1H),8.74(s,1H),8.19(s,1H),8.13(t ,J=9.2Hz,1H),7.40-7.37(m,2H),7.31(dd,J1=11.6Hz,J2=2.8Hz,1H),7.09- 7.07(m,2H),7.04(dd,J1=9.2Hz,J2=2.4Hz,1H),6.36(s,1H),4.02(d,J=6.8H z,2H),2.78-2.71(m,1H),2.12-2.05(m,2H),1.96-1.81(m,4H),1.27(s,9H).

[0366] Example 13 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3,4-dimethoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 13)

[0367]

[0368] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with 3,4-dimethoxyphenylhydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3,4-dimethoxyphenyl)-1H-pyrazol-5-yl)urea.

[0369] ESI-MS: m / z = 547.0 [M+H] + .

[0370] 1 H NMR (400MHz, DMSO-d6): δ9.01(d,J=2.0Hz,1H),8.75(s,1H),8.19(s,1H),8.14(t,J=8.8Hz,1H),7.31(dd,J1=11. 6Hz, J2=2.8Hz,1H),7.11(d,J=8.8Hz,1H),7.06-6.99(m,3H),6.38(s,1H),3.82(s,3H),3.80(s,3H),1.27(s,9H).

[0371] Example 14 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-ethoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 14)

[0372]

[0373] Referring to steps 1 to 3 in Example 8, M3 was replaced by M5 to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-ethoxyphenyl)-1H-pyrazol-5-yl)urea.

[0374] ESI-MS: m / z = 531.0 [M+H] + .

[0375] 1H NMR (400MHz, DMSO-d6): δ9.02(d,J=2.4Hz,1H),8.85(s,1H),8.19(s,1H),8.11(t,J=9.2Hz,1H),7.45(t,J=9.2Hz,1H),7.31(dd,J1=12.0Hz, J2=2.8Hz,1H),7.09-7.01(m,3H),6.99(dd,J1=8.4Hz,J2=1.6Hz,1H),6.40(s,1H),4.10(q,J=7.2Hz,2H),1.35(t,J=7.2Hz,3H),1.28(s,9H).

[0376] Example 15 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-propoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 15)

[0377]

[0378] Referring to steps 1 to 3 in Example 8, M3 was replaced by M5, and iodoethane was replaced by 1-iodopropane to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-propoxyphenyl)-1H-pyrazol-5-yl)urea.

[0379] ESI-MS: m / z = 545.0 [M + H] + .

[0380] 1 H NMR (400MHz, DMSO-d6): δ9.02(d,J=2.4Hz,1H),8.85(s,1H),8.19(s,1H),8.10( t,J=9.2Hz,1H),7.45(t,J=8.4Hz,1H),7.31(dd,J1=7.6Hz,J2=2.8Hz,1H),7.09- 7.07(m,1H),7.05-7.01(m,2H),7.00(d,J1=8.4Hz,J2=2.4Hz,1H),6.39(s,1H), 3.99(t,J=6.4Hz,2H),1.76(q,J=7.2Hz,2H),1.28(s,9H),0.98(t,J=7.6Hz,3H).

[0381] Example 16 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-propoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 16)

[0382]

[0383] Referring to steps 1 to 3 in Example 8, M3 was replaced by M5, and iodoethane was replaced by 2-iodopropane to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-propoxyphenyl)-1H-pyrazol-5-yl)urea.

[0384] ESI-MS: m / z = 545.0 [M + H] + .

[0385] 1 H NMR (400MHz, DMSO-d6): δ9.00(d,J=2.0Hz,1H),8.85(s,1H),8.19(s,1H),8.10(t,J=9.2Hz,1H),7.44(t,J=8.0Hz,1H),7.31(dd,J1 =11.6Hz, J2=2.4Hz,1H),7.07-7.01(m,3H),6.98(dd,J1=8.4Hz,J2=2.4Hz,1H),6.38(s,1H),4.68-4.62(m,1H),1.28-1.26(m,15H).

[0386] Example 17 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(benzo[d][1,3]dioxol-5-yl)-3-(tert-butyl)-1H-pyrazol-5-yl)urea (Compound 17)

[0387]

[0388] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with benzo[d][1,3]dioxol-5-ylhydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(benzo[d][1,3]dioxol-5-yl)-3-(tert-butyl)-1H-pyrazol-5-yl)urea.

[0389] ESI-MS: m / z = 531.0 [M+H] + .

[0390] 1 H NMR (400MHz, DMSO-d6): δ9.00(d,J=2.0Hz,1H),8.80(s,1H),8.19(s,1H),8.13(t,J=8.8Hz,1H),7.31(dd,J1=11. 6Hz, J2=2.4Hz, 1H), 7.08-7.01 (m, 3H), 6.96 (dd, J1=8.0Hz, J2=2.0Hz, 1H), 6.36 (s, 1H), 6.13 (s, 2H), 1.26 (s, 9H).

[0391] Example 18 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(2,2-difluorobenzo[d][1,3]dihydroxy-5-yl)-1H-pyrazol-5-yl)urea (Compound 18)

[0392]

[0393] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with (2,2-difluorobenzo[d][1,3]dioxol-5-yl)hydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(2,2-difluorobenzo[d][1,3]dihydroxy-5-yl)-1H-pyrazol-5-yl)urea.

[0394] ESI-MS: m / z = 567.0 [M+H] + .

[0395] 1 H NMR (400MHz, DMSO-d6): δ8.93(d,J=2.0Hz,1H),8.87(s,1H),8.19(s,1H),8.10(t,J=9.6Hz,1H),7.68(d,J=2.0Hz,1H),7.60(d,J=8.8Hz,1 H),7.38(dd,J1=8.8Hz,J2=2.0Hz,1H),7.31(dd,J1=11.6Hz,J2=2.4Hz,1H),7.05(dt,J1=8.8Hz,J2=1.6Hz,1H),6.41(s,1H),1.27(s,9H).

[0396] Example 19 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)methyl)phenyl)-1H-pyrazol-5-yl)urea (Compound 19)

[0397]

[0398] Step 1: Synthesis of 4-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)benzoic acid

[0399] Dissolve 4-carboxylic acid phenylhydrazine hydrochloride (3.0 g, 15.96 mmol) and cyanopinacolone (2.7 g, 17.55 mmol) in toluene (15 mL), add triethylamine (1.77 g, 17.55 mmol), react at 100°C for 1 h, and stop the reaction; cool the system to room temperature, concentrate under reduced pressure, and purify the residue by column chromatography, using 0-10% methanol in dichloromethane as the eluent to obtain 2.0 g of 4-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)benzoic acid, with a yield of 48.4%;

[0400] ESI-MS: m / z = 260.0 [M + H] + .

[0401] Step 2: Synthesis of (4-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)phenyl)methanol

[0402] Dissolve 4-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)benzoic acid (200 mg, 3.86 mmol) in ultra-dry tetrahydrofuran (20 mL), add borane tetrahydrofuran solution (15 mL, 15.00 mmol) dropwise at 0°C, react at room temperature for 3 h, and stop the reaction; add 1N HCl (20 mL) dropwise to the system at 0°C to quench, extract with ethyl acetate three times (3 times, 20 mL each time), combine the organic phases, wash with saturated brine (50 mL), dry with anhydrous sodium sulfate, filter, and concentrate the filtrate under reduced pressure. The residue is purified by column chromatography, the eluent is 0-2% methanol in dichloromethane solution, and 650 mg of (4-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)phenyl)methanol is obtained, with a yield of 68.7%;

[0403] ESI-MS: m / z = 246.0 [M+H] + .

[0404] Step 3: Synthesis of 3-(tert-butyl)-1-(4-(chloromethyl)phenyl)-1H-pyrazol-5-amine

[0405] Dissolve (4-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)phenyl)methanol (250mg, 1.00mmol) in dichloromethane (10mL), add thionyl chloride (180mg, 1.50mmol) dropwise at 0°C, react at room temperature for 1h, and stop the reaction; quench with water, extract with dichloromethane three times (3 times, 20mL each time), combine the organic phases, wash with saturated brine (50mL), dry with anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure. The residue is purified by column chromatography, the eluent is 0-15% ethyl acetate in petroleum ether solution, and 110mg of 3-(tert-butyl)-1-(4-(chloromethyl)phenyl)-1H-pyrazol-5-amine is obtained, with a yield of 41.8%;

[0406] ESI-MS: m / z = 264.0 [M+H] + .

[0407] Step 4: Synthesis of 3-(tert-butyl)-1-(4-((dimethylamino)methyl)phenyl)-1H-pyrazol-5-amine

[0408] 3-(tert-butyl)-1-(4-(chloromethyl)phenyl)-1H-pyrazole-5-amine (110 mg, 0.42 mmol) and dimethylamine hydrochloride (135 mg, 1.67 mmol) were dissolved in N,N-dimethylformamide (5 mL), potassium carbonate (116 mg, 0.84 mmol) was added, and the reaction was carried out at 60°C for 1 h to stop the reaction. The reaction solution was quenched with water, extracted with ethyl acetate three times (3 times, 10 mL each time), the organic phases were combined, washed once with water (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 37 mg of 3-(tert-butyl)-1-(4-((dimethylamino)methyl)phenyl)-1H-pyrazole-5-amine, with a yield of 32.3%.

[0409] ESI-MS: m / z = 273.0 [M+H] + .

[0410] Step 5: Synthesis of phenyl (3-(tert-butyl)-1-(4-((dimethylamino)methyl)phenyl)-1H-pyrazol-5-yl)carbamate

[0411] 3-(tert-butyl)-1-(4-((dimethylamino)methyl)phenyl)-1H-pyrazol-5-amine (108 mg, 0.40 mmol) and triethylamine (45 mg, 0.45 mmol) were dissolved in tetrahydrofuran (5 mL), and phenyl chloroformate was added dropwise at 0°C. The reaction was allowed to react for 30 min at room temperature to stop the reaction. The system was quenched with water, extracted three times with ethyl acetate (3 times, 10 mL each time), the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography, the eluent being a 0-45% ethyl acetate solution in petroleum ether, to obtain 120 mg of phenyl (3-(tert-butyl)-1-(4-((dimethylamino)methyl)phenyl)-1H-pyrazol-5-yl)carbamate, with a yield of 76.5%.

[0412] ESI-MS: m / z = 393.0 [M+H] + .

[0413] Step 6: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)methyl)phenyl)-1H-pyrazol-5-yl)urea

[0414] Phenyl (3-(tert-butyl)-1-(4-((dimethylamino)methyl)phenyl)-1H-pyrazol-5-yl)carbamate (71 mg, 0.18 mmol) and 4-amino-6-(4-amino-3-fluorophenoxy)pyrimidine-5-carbonitrile (44 mg, 0.18 mmol) were dissolved in tetrahydrofuran (5 mL), triethylamine (55 mg, 0.54 mmol) was added, and the reaction was carried out at 65°C for 1 hour to stop the reaction. The system was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography, and the eluent was 0-5% methanol in dichloromethane solution. The preparation and purification gave 14 mg of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)methyl)phenyl)-1H-pyrazol-5-yl)urea, with a yield of 14.3%.

[0415] ESI-MS: m / z = 544.0 [M+H] + .

[0416] 1H NMR (400MHz, DMSO-d6): δ8.99(d,J=2.4Hz,1H),8.87(s,1H),8.19(s,1H),8.17(s,1H),8.10(t,J=8.8Hz,1H),7.49-7. 44(m,4H),7.30(dd,J1=11.6Hz,J2=2.4Hz,1H),7.04-7.01(m,1H),6.39(s,1H),3.49(s,2H),2.21(s,6H),1.28(s,9H).

[0417] Example 20 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(pyrrolidin-1-ylmethyl)phenyl)-1H-pyrazol-5-yl)urea (Compound 20)

[0418]

[0419] Step 1: Synthesis of 3-(tert-butyl)-1-(4-(pyrrolidin-1-ylmethyl)phenyl)-1H-pyrazol-5-amine

[0420] 3-(tert-butyl)-1-(4-(chloromethyl)phenyl)-1H-pyrazole-5-amine (75 mg, 0.30 mmol) and tetrahydropyrrole (72 mg, 1.20 mmol) were dissolved in N,N-dimethylformamide (3 mL), potassium carbonate (81 mg, 0.60 mmol) was added, and the reaction was carried out at 60°C for 1 h to stop the reaction. The reaction solution was quenched with water, extracted with ethyl acetate three times (3 times, 10 mL each time), the organic phases were combined, washed once with water, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 50 mg of 3-(tert-butyl)-1-(4-(pyrrolidin-1-ylmethyl)phenyl)-1H-pyrazole-5-amine, with a yield of 55.9%.

[0421] ESI-MS: m / z = 299.0 [M+H] + .

[0422] Step 2: Synthesis of 3-(tert-butyl)-1-(4-(pyrrolidin-1-ylmethyl)phenyl)-1H-pyrazol-5-amine

[0423] 3-(tert-butyl)-1-(4-(pyrrolidin-1-ylmethyl)phenyl)-1H-pyrazol-5-amine (119 mg, 0.40 mmol) and triethylamine (45 mg, 0.45 mmol) were dissolved in tetrahydrofuran (5 mL), and phenyl chloroformate was added dropwise at 0°C. The reaction was allowed to react for 30 min at room temperature to stop the reaction. The system was quenched with water, extracted three times with ethyl acetate (3 times, 10 mL each time), the organic phases were combined, washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography, the eluent being a 0-45% ethyl acetate solution in petroleum ether, to obtain 134 mg of phenyl (3-(tert-butyl)-1-(4-((dimethylamino)methyl)phenyl)-1H-pyrazol-5-yl)carbamate, with a yield of 80.1%.

[0424] ESI-MS: m / z = 419.0 [M+H] + .

[0425] Step 3: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(pyrrolidin-1-ylmethyl)phenyl)-1H-pyrazol-5-yl)urea

[0426] Phenyl (3-(tert-butyl)-1-(4-((dimethylamino)methyl)phenyl)-1H-pyrazol-5-yl)carbamate (17 mg, 0.04 mmol) and 4-amino-6-(4-amino-3-fluorophenoxy)pyrimidine-5-carbonitrile (10 mg, 0.04 mmol) were dissolved in tetrahydrofuran (5 mL), triethylamine (13 mg, 0.13 mmol) was added, and the reaction was carried out at 65°C for 1 hour to stop the reaction. The system was cooled to room temperature and concentrated under reduced pressure. The residue was purified by column chromatography, and the eluent was 0-5% methanol in dichloromethane solution. The preparation and purification gave 10 mg of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(pyrrolidin-1-ylmethyl)phenyl)-1H-pyrazol-5-yl)urea, with a yield of 44.1%.

[0427] ESI-MS: m / z = 570.0 [M + H] + .

[0428] 1H NMR (400MHz, DMSO-d6): δ9.00(d,J=2.4Hz,1H),8.87(s,1H),8.19(s,1H),8.17(s,1H),8.11(t,J=9.2Hz,1H),7.47(s,4H),7.30 (dd, J1=11.6Hz, J2=2.4Hz,1H),7.04-7.01(m,1H),6.39(s,1H),3.68(s,2H),2.53-2.51(m,4H),1.74-1.71(m,4H),1.28(s,9H).

[0429] Example 21 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-cyclohexyl-1H-pyrazol-5-yl)urea (Compound 21)

[0430]

[0431] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with cyclohexylhydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-cyclohexyl-1H-pyrazol-5-yl)urea.

[0432] ESI-MS: m / z = 493.0 [M+H] + .

[0433] 1 H NMR (400MHz, DMSO-d6): δ8.77(d,J=2.0Hz,1H),8.74(s,1H),8.20(s,1H),8.13(t,J=9.2Hz,1H),7.34(dd,J1=11.6Hz,J2=2.4Hz ,1H),7.06-7.02(m,1H),6.06(s,1H),3.97-3.92(m,1H),1.84-1.73(m,6H),1.67-1.64(m,1H),1.38-1.35(m,2H),1.21(s,10H).

[0434] Example 22 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(difluoromethoxy)phenyl)-1H-pyrazol-5-yl)urea (Compound 22)

[0435]

[0436] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with (4-(difluoromethoxy)phenyl)hydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(difluoromethoxy)phenyl)-1H-pyrazol-5-yl)urea.

[0437] ESI-MS: m / z = 553.0 [M+H] + .

[0438] 1 H NMR (400MHz, DMSO-d6): δ8.97(d,J=2.0Hz,1H),8.88(s,1H),8.19(s,1H),8.11(t,J=9.2Hz,1H),7.60-7.57(m,2H ),7.50(t,J=74.0Hz,1H),7.36(d,J=8.8Hz,2H),7.31-7.27(m,1H),7.04-7.01(m,1H),6.40(s,1H),1.28(s,9H).

[0439] Example 23 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 23)

[0440]

[0441] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with (3-fluoro-4-methoxyphenyl)hydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0442] ESI-MS: m / z = 535.0 [M+H] + .

[0443] 1H NMR (400MHz, DMSO-d6): δ8.96(d,J=2.0Hz,1H),8.79(s,1H),8.19(s,1H),8.11(t,J=9.2Hz,1H),7.45(dd,J1=12. 4Hz, J2=2.4Hz,1H),7.36-7.25(m,3H),7.07(dt,J1=9.2Hz,J2=1.6Hz,1H),6.38(s,1H),3.91(s,3H),1.27(s,9H).

[0444] Example 24 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(2-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 24)

[0445]

[0446] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with (2-fluoro-4-methoxyphenyl)hydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(2-fluoro-4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0447] ESI-MS: m / z = 535.0 [M+H] + .

[0448] 1 H NMR (400MHz, DMSO-d6): δ8.90(d,J=2.4Hz,1H),8.77(s,1H),8.18(s,1H),8.15(t,J=9.2Hz,1H),7.49(t,J=9.2Hz,1H),7.31(dd,J1=12.0Hz,J2 =2.8Hz,1H),7.15(dd,J1=12.4Hz,J2=2.8Hz,1H),7.04(dt,J1=8.8Hz,J2=1.6Hz,1H),6.98-6.93(m,1H),6.38(s,1H),3.86(s,3H),1.26(s,9H).

[0449] Example 25 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(6-methoxypyridin-3-yl)-1H-pyrazol-5-yl)urea (Compound 25)

[0450]

[0451] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with 5-hydrazine-2-methoxypyridine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(6-methoxypyridin-3-yl)-1H-pyrazol-5-yl)urea.

[0452] ESI-MS: m / z = 518.0 [M+H] + .

[0453] 1 H NMR (400MHz, DMSO-d6): δ8.93(d,J=2.4Hz,1H),8.84(s,1H),8.33(dd,J1=2.8Hz,J2=0.8Hz,1H),8.19(s,1H),8.12(t,J=8.8Hz, 1H),7.86(dd,J1=8.8Hz,J2=2.8Hz,1H),7.31(dd,J=12.0,2.8Hz,1H),7.06-6.97(m,2H),6.40(s,1H),3.93(s,3H),1.27(s,9H).

[0454] Example 26 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3,5-difluoro-4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 26)

[0455]

[0456] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with (3,5-difluoro-4-methoxyphenyl)hydrazine hydrochloride to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(3,5-difluoro-4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0457] ESI-MS: m / z = 553.0 [M+H] + .

[0458] 1H NMR (400MHz, DMSO-d6): δ8.96(d,J=1.2Hz,1H),8.88(s,1H),8.19(s,1H),8.07(t,J=8.8Hz,1H),7.46-7. 36(m,2H),7.32(dd,J1=11.6Hz,J2=2.4Hz,1H),7.05-7.02(m,1H),6.41(s,1H),3.97(s,3H),1.27(s,9H).

[0459] Example 27 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-ethoxy-3-fluorophenyl)-1H-pyrazol-5-yl)urea (Compound 27)

[0460]

[0461] Referring to step 2 in intermediate M3, steps 1 to 3 in Example 8 are performed by replacing p-methoxyphenylhydrazine hydrochloride with 3-(tert-butyl)-1-(3-fluoro-4-methoxyphenyl)-1H-pyrazol-5-amine to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-ethoxy-3-fluorophenyl)-1H-pyrazol-5-yl)urea.

[0462] ESI-MS: m / z = 549.0 [M+H] + .

[0463] 1 H NMR (400MHz, DMSO-d6): δ8.96(s,1H),8.80(s,1H),8.19(s,1H),8.11(t,J=9.2Hz,1H),7.46(dd,J1=12.4Hz,J2=2.4Hz ,1H),7.32-7.25(m,3H),7.04(d,J=8.8Hz,1H),6.37(s,1H),4.20(q,J=6.8Hz,2H),1.40(t,J=6.8Hz,3H),1.27(s,9H).

[0464] Example 28 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-ethoxy-3,5-difluorophenyl)-1H-pyrazol-5-yl)urea (Compound 28)

[0465]

[0466] Referring to step 2 in intermediate M3, steps 1 to 3 in Example 8 are performed by replacing p-methoxyphenylhydrazine hydrochloride with 3-(tert-butyl)-1-(3,5-difluoro-4-methoxyphenyl)-1H-pyrazol-5-amine to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-ethoxy-3,5-difluorophenyl)-1H-pyrazol-5-yl)urea.

[0467] ESI-MS: m / z = 567.0 [M+H] + .

[0468] 1 H NMR (400MHz, DMSO-d6): δ8.97(s,1H),8.89(s,1H),8.20(s,1H),8.06(t,J=9.2Hz,1H),7.45-7.36(m,2H),7.32(dd,J 1=12.0Hz,J2=2.8Hz,1H),7.05-7.02(m,1H),6.41(s,1H),4.23(q,J=6.8Hz,2H),1.35(t,J=6.8Hz,3H),1.27(s,9H).

[0469] Example 29 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(4-methoxyphenyl)-3-(1-methylcyclobutyl)-1H-pyrazol-5-yl)urea (Compound 29)

[0470]

[0471] Step 1: Synthesis of 3-(1-methylcyclobutyl)-3-oxopropionitrile

[0472] Anhydrous acetonitrile (410 mg, 10.00 mmol) was added to anhydrous tetrahydrofuran (10 mL), the system was replaced with nitrogen, and a tetrahydrofuran solution of lithium diisopropylamide (2.0 M, 10 mL) was added at -78 ° C, the temperature was maintained and stirred for 1 hour, and a tetrahydrofuran solution (4 mL) of 1-methylcyclobutane-1-carboxylic acid methyl ester (1.02 g, 8.00 mmol) was slowly added dropwise, and the mixture was heated to room temperature for 2 hours. After the reaction was completed, a saturated ammonium chloride solution (60 mL) was slowly added dropwise to quench, and the mixture was extracted with ethyl acetate (3 times, 30 mL each time), the organic phases were combined, washed once with saturated brine (60 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure to obtain 830 mg of 3-(1-methylcyclobutyl)-3-oxopropionitrile, with a yield of 75.7%.

[0473] ESI-MS: m / z = 138.0 [M + H]+ .

[0474] Step 2: Synthesis of 1-(4-methoxyphenyl)-3-(1-methylcyclobutyl)-1H-pyrazol-5-amine

[0475] Dissolve p-methoxyphenylhydrazine hydrochloride (174 mg, 1.00 mmol) and 3-(1-methylcyclobutyl)-3-oxopropionitrile (138 mg, 1.00 mmol) in toluene (4 mL), and heat the system under reflux overnight. The solvent was dried, and the residue was separated by column chromatography, with the eluent being 10-30% ethyl acetate in petroleum ether solution, to obtain 141 mg of 1-(4-methoxyphenyl)-3-(1-methylcyclobutyl)-1H-pyrazole-5-amine, with a yield of 54.9%;

[0476] ESI-MS: m / z = 258.0 [M+H] + .

[0477] Step 3: Synthesis of phenyl (3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl)carbamate

[0478] Dissolve 1-(4-methoxyphenyl)-3-(1-methylcyclobutyl)-1H-pyrazole-5-amine (200 mg, 0.78 mmol) in dichloromethane (5 mL), add triethylamine (118 mg, 1.17 mmol), add phenyl chloroformate (146 mg, 0.93 mmol) dropwise under ice bath, and keep the temperature for 4 hours. The reaction solution is quenched with water, extracted with dichloromethane three times (3 times, 20 mL each time), the organic phases are combined, washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate is concentrated under reduced pressure to obtain 150 mg of phenyl (3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazole-5-yl) carbamate, with a yield of 51.1%.

[0479] ESI-MS: m / z = 378.0 [M+H] + .

[0480] Step 4: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(4-methoxyphenyl)-3-(1-methylcyclobutyl)-1H-pyrazol-5-yl)urea

[0481] Phenyl (3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl) carbamate (150 mg, 0.40 mmol), 4-amino-6-(4-amino-3-methylphenoxy) pyrimidine-5-carbonitrile (97 mg, 0.40 mmol) and triethylamine (60 mg, 0.60 mmol) were dissolved in tetrahydrofuran (5 mL), and the temperature was raised to 70 ° C for 4 hours. The system was cooled to room temperature, quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), and the organic phases were combined, washed with water once (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with 0-3% methanol in dichloromethane as the eluent to give 130 mg of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(4-methoxyphenyl)-3-(1-methylcyclobutyl)-1H-pyrazol-5-yl)urea in a yield of 61.9%.

[0482] ESI-MS: m / z = 529.0 [M+H] + .

[0483] 1 H NMR (400MHz, DMSO-d6): δ8.98(d,J=2.0Hz,1H),8.78(s,1H),8.19(s,1H),8.14(t,J=9.2Hz,1H),7.47-7.40(m,2H),7.31(dd,J1=11.6 Hz,J2=2.4Hz,1H),7.14-7.06(m,2H),7.05-7.01(m,1H),6.37(s,1H),3.83(s,3H),2.45-2.34(m,2H),2.07-1.80(m,4H),1.46(s,3H).

[0484] Example 30 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazol-5-yl)urea (Compound 30)

[0485]

[0486] Referring to steps 1 to 4 in Intermediate Example 29, 1-methylcyclobutane-1-carboxylic acid methyl ester was replaced with 2,2,2-trifluoroacetic acid methyl ester to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(4-methoxyphenyl)-3-trifluoromethyl-1H-pyrazol-5-yl)urea.

[0487] ESI-MS: m / z = 529.0 [M+H] + .

[0488] 1 H NMR (400MHz, DMSO-d6): δ9.09 (s, 2H), 8.19 (s, 1H), 8.12 (t, J = 9.2Hz, 1H), 7.56-7.50 (m, 2H), 7.3 3(dd,J1=12.0Hz, J2=2.8Hz,1H),7.19-7.14(m,2H),7.07-7.04(m,1H),6.86(s,1H),3.86(s,3H).

[0489] Example 31 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-cyclopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 31)

[0490]

[0491] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced by 4-methoxyphenylhydrazine hydrochloride, and pivaloylacetonitrile was replaced by 3-cyclopropyl-3-oxopropionitrile to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-cyclopropyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0492] ESI-MS: m / z = 501.0 [M+H] + .

[0493] 1 H NMR (400MHz, DMSO-d6): δ8.96(d,J=2.0Hz,1H),8.76(s,1H),8.18(s,1H),8.11(t,J=9.2Hz,1H),7.44-7.36(m,2H),7.30(dd,J1=12.0Hz, J2=2.8Hz,1H),7.14-7.07(m,2H),7.04-7.10(m,1H),6.16(s,1H),3.82(s,3H),1.89-1.83(m,1H),0.92-0.81(m,2H),0.72-0.61(m,2H).

[0494] Example 32 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(4-methoxyphenyl)-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)urea (Compound 32)

[0495]

[0496] Step 1: Synthesis of 3-(1-methylcyclopropyl)-3-oxopropionitrile

[0497] Acetonitrile (360 mg, 8.76 mmol) was dissolved in anhydrous tetrahydrofuran (10 mL), the system was replaced with nitrogen, and a tetrahydrofuran solution of lithium diisopropylamide (2.0 M, 4.4 mL) was added at -78 ° C, the temperature was maintained and stirred for 1 hour, and then 1-methylcyclopropane-1-carboxylic acid methyl ester (500 mg, 4.38 mmol) was slowly added, and the temperature was raised to -10 ° C for 3 hours. After the reaction was completed, saturated ammonium chloride solution was added to quench, the reaction solution was extracted with ethyl acetate (3 times, 10 mL each time), and then the organic phase was washed with saturated brine (3 times, 30 mL each time), dried, filtered, and concentrated to obtain 500 mg of (3-(1-methylcyclopropyl)-3-oxopropionitrile, with a yield of 92.7%.

[0498] ESI-MS: m / z = 124.0 [M + H] + .

[0499] Step 2: Synthesis of (1-(4-methoxyphenyl)-3-(1-methylcyclopropyl)-1H-pyrazol-5-amine

[0500] Dissolve (4-methoxyphenyl)hydrazine hydrochloride (500 mg, 2.86 mmol) in toluene (10 mL), then add 3-(1-methylcyclopropyl)-3-oxopropionitrile (388 mg, 3.15 mmol) and triethylamine (869 mg, 8.59 mmol), and react at 110°C for 2 h. After the reaction is completed, cool to room temperature, add water (20 mL) to the reaction solution, then extract the reaction solution with ethyl acetate (3 times, 10 mL each time), separate the liquid to obtain the organic phase, dry it over anhydrous sodium sulfate, filter it, and concentrate it under reduced pressure. The residue is separated and purified by column chromatography, and the eluent is a 20-30% ethyl acetate petroleum ether solution to obtain 1-(4-methoxyphenyl)-3-(1-methylcyclopropyl)-1H-pyrazole-5-amine 270 mg, with a yield of 38.8%.

[0501] ESI-MS: m / z = 244.0 [M+H] + .

[0502] Step 3: Synthesis of phenyl (1-(4-methoxyphenyl)-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)carbamate

[0503] Dissolve (1-(4-methoxyphenyl)-3-(1-methylcyclopropyl)-1H-pyrazol-5-amine (200 mg, 0.82 mmol) in dichloromethane (5 mL), add triethylamine (125 mg, 1.23 mmol), add phenyl chloroformate (128 mg, 0.82 mmol) dropwise under ice bath, and keep the temperature to react for 4 hours. The reaction solution is quenched with water, extracted with dichloromethane three times (3 times, 20 mL each time), the organic phases are combined, washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate is concentrated under reduced pressure to obtain 152 mg of phenyl (3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl) carbamate, with a yield of 50.8%.

[0504] ESI-MS: m / z = 364.0 [M+H] + .

[0505] Step 5: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(4-methoxyphenyl)-3-(1-methylcyclopropyl)-1H-pyrazol-5-yl)urea

[0506] Phenyl (1- (4-methoxyphenyl) -3- (1-methylcyclopropyl) -1H-pyrazol-5-yl) carbamate (54mg, 0.15mmol) was dissolved in tetrahydrofuran (5mL), 4-amino-6- (4-amino-3-methylphenoxy) pyrimidine-5-carbonitrile (36mg, 0.15mmol) and triethylamine (30mg, 0.30mmol) were added, and the temperature was raised to 60°C for 2 hours. After cooling to room temperature, the reaction solution was concentrated, and the residue was purified by column chromatography, the eluent being 0-3% methanol in dichloromethane solution, to obtain the target product 1- (4- ( (6-amino-5-cyanopyrimidin-4-yl) oxy) -2-fluorophenyl) -3- (1- (4-methoxyphenyl) -3- (1-methylcyclopropyl) -1H-pyrazol-5-yl 23mg, the yield was 30.2%.

[0507] ESI-MS: m / z = 515.0 [M + H] + .

[0508] 1H NMR (400MHz, DMSO-d6): δ8.96(s,1H),8.75(s,1H),8.19(s,1H),8.12(t,J=9.2Hz,1H),7.96(s,2H),7.40(d,J=8.8Hz,2H),7.30(dd,J1=12.0 Hz,J2=2.8Hz,1H),7.10(d,J=8.4Hz,2H),7.04(d,J=8.8Hz,2H),6.22(s,1H),3.82(s,3H),1.38(s,3H),0.91-0.88(m,2H),0.72-0.93(m,2H).

[0509] Example 33 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-cyclobutyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 33)

[0510]

[0511] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with (4-methoxyphenyl)hydrazine hydrochloride, and pivaloylacetonitrile was replaced with 3-cyclobutyl-3-oxopropionitrile to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-cyclobutyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0512] ESI-MS: m / z = 515.0 [M + H] + .

[0513] 1 H NMR (400MHz, DMSO-d6): δ8.99(d,J=2.4Hz,1H),8.82(s,1H),8.19(s,1H),8.12(t, J=9.2Hz,1H),7.47-7.37(m,2H),7.30(dd,J1=11.6Hz,J2=2.4Hz,1H),7.13-7.07( m,2H),7.05(dt,J1=8.8Hz,J2=1.2Hz,1H),6.37(s,1H),3.82(s,3H),3.49-3.40(m ,1H),2.30-2.21(m,2H),2.20-2.09(m,2H),2.03-1.91(m,1H),1.88-1.81(m,1H).

[0514] Example 34 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(2-cyanopropane-2-yl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 34)

[0515]

[0516] Referring to steps 1 to 4 in Example 32, 1-methylcyclopropane-1-carboxylic acid methyl ester was replaced with 2-cyano-2-methylpropionic acid methyl ester, and (4-methoxyphenyl)hydrazine hydrochloride was replaced with phenylhydrazine to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(2-cyanopropane-2-yl)-1-phenyl-1H-pyrazol-5-yl)urea.

[0517] ESI-MS: m / z = 498.0 [M + H] + .

[0518] 1 H NMR (400MHz, DMSO-d6): δ9.07(s,1H),9.04(s,1H),8.19(s,1H),8.12(t,J=9.2Hz,1H),7.63-7.54(m,4H ),7.54-7.48(m,1H),7.32(dd,J1=11.6Hz,J2=2.4Hz,1H),7.06-7.02(M,1H),6.61(s,1H),1.70(s,6H).

[0519] Example 35 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(4-methoxyphenyl)-3-(1-(trifluoromethyl)cyclopropyl)-1H-pyrazol-5-yl)urea (Compound 35)

[0520]

[0521] Referring to steps 1 to 4 in Example 32, 1-methylcyclopropane-1-carboxylic acid methyl ester was replaced with 1-(trifluoromethyl)cyclopropane-1-carboxylic acid methyl ester to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(4-methoxyphenyl)-3-(1-(trifluoromethyl)cyclopropyl)-1H-pyrazol-5-yl)urea.

[0522] ESI-MS: m / z = 569.0 [M+H] + .

[0523] 1H NMR (400MHz, DMSO-d6): δ9.06(d,J=2.0Hz,1H),8.94(s,1H),8.19(s,1H),8.13(t,J=9.2Hz,1H),7.47-7.40(m,2H),7.31(dd,J 1=11.6Hz,J2=2.4Hz,1H),7.14-7.08(m,2H),7.05(dt,J1=9.2Hz,J2=1.6Hz,1H),6.56(s,1H),3.83(s,3H),1.36-1.26(m,4H).

[0524] Example 36 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-cyclopentyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 36)

[0525]

[0526] Referring to steps 1 to 3 in Example 2, 4-trifluoromethoxyphenylhydrazine hydrochloride was replaced with (4-methoxyphenyl)hydrazine hydrochloride, and pivaloylacetonitrile was replaced with 3-cyclopentyl-3-oxopropionitrile to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-cyclopentyl-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0527] ESI-MS: m / z = 529.0 [M+H] + .

[0528] 1 H NMR (400MHz, DMSO-d6): δ8.96(d,J=2.0Hz,1H),8.76(s,1H),8.19(s,1H),8.13(t,J=9.2Hz,1H),7.45-7.37(m,2H),7.30(dd,J1=11.6Hz, J2=2.4Hz,1H),7.15-7.07(m,2H),7.04-7.01(m,1H),6.30(s,1H),3.82(s,3H),3.03-2.95(m,1H),2.03-1.90(m,2H),1.77-1.56(m,6H).

[0529] Example 37 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(4-methoxyphenyl)-3-(1-(trifluoromethyl)cyclobutyl)-1H-pyrazol-5-yl)urea (Compound 37)

[0530]

[0531] Referring to steps 1 to 4 in Example 32, 1-methylcyclopropane-1-carboxylic acid methyl ester was replaced with 1-(trifluoromethyl)cyclobutane-1-carboxylic acid ethyl ester to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(1-(4-methoxyphenyl)-3-(1-(trifluoromethyl)cyclobutyl)-1H-pyrazol-5-yl)urea.

[0532] ESI-MS: m / z = 583.0 [M+H] + .

[0533] 1 H NMR (400MHz, DMSO-d6): δ9.05(d,J=2.4Hz,1H),8.92(s,1H),8.19(s,1H),8.14(t,J=9.2Hz,1H),7.51-7.44(m,2H),7.32(dd,J1= 11.6Hz, J2=2.4Hz,1H),7.17-7.10(m,2H),7.06-7.00(m,1H),6.49(s,1H),3.84(s,3H),2.58(t,J=8.0Hz,4H),2.03-1.97(m,2H).

[0534] Example 38 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 38)

[0535]

[0536] Step 1: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl)urea

[0537] Phenyl (3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl) carbamate (40 mg, 0.11 mmol), 4-amino-6-(4-amino-3-methylphenoxy) pyrimidine-5-carbonitrile (25 mg, 0.11 mmol) and triethylamine (16 mg, 0.16 mmol) were dissolved in tetrahydrofuran (5 mL), and the temperature was raised to 70 ° C for 4 hours. The system was cooled to room temperature, quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), and the organic phases were combined, washed with water once (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with 0-3% methanol in dichloromethane as the eluent to give 12 mg of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl)urea in a yield of 21.6%.

[0538] ESI-MS: m / z = 527.0 [M+H] + .

[0539] 1 H NMR (400MHz, DMSO-d6): δ8.67(s,1H),8.29(s,1H),8.17(s,1H),8.01(s,2H),7.70(d,J=8.8Hz,1H),7.42(d,J=8.8Hz,2H),7.07-7. 04(m,3H),6.99(dd,J1=8.8Hz,J2=2.8Hz,1H),6.32(s,1H),4.11(q,J=6.8Hz,2H),2.17(s,3H),1.37(t,J=6.8Hz,3H),1.26(s,9H).

[0540] Example 39 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)phenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 39)

[0541]

[0542] Step 1: Synthesis of 4-amino-6-(4-aminophenoxy)pyrimidine-5-carbonitrile

[0543] 4-Amino-6-chloropyrimidine-5-carbonitrile (154 mg, 1.00 mmol) was dissolved in DMF (5 mL), cesium carbonate (652 mg, 2.00 mmol) and 4-aminophenol (131 mg, 1.2 mmol) were added, and microwave reaction was carried out at 90 ° C for 1 hour. After the reaction was completed, it was cooled to room temperature, quenched with water (20 mL), extracted with ethyl acetate (3 times, 10 mL each time), and the organic phases were combined, washed with water (20 ml), and then washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography, and the eluent was 0-50% ethyl acetate in petroleum ether to obtain 108 mg of 4-amino-6-(4-aminophenoxy)pyrimidine-5-carbonitrile, with a yield of 47.6%.

[0544] ESI-MS: m / z = 228.0 [M+H] + .

[0545] Step 2: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)phenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea

[0546] Phenyl (3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl) carbamate (37 mg, 0.10 mmol), 4-amino-6-(4-aminophenoxy)pyrimidine-5-carbonitrile (23 mg, 0.10 mmol) and triethylamine (15 mg, 0.15 mmol) were dissolved in tetrahydrofuran (5 mL), and the temperature was raised to 70 ° C for 4 hours. The system was cooled to room temperature, quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), and the organic phases were combined, washed with water once (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with 0-3% methanol in dichloromethane as the eluent to give 23 mg of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)phenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea in a yield of 46.2%.

[0547] ESI-MS: m / z = 499.0 [M+H] + .

[0548] 1 H NMR (400MHz, DMSO-d6): δ9.08(s,1H),8.30(s,1H),8.16(s,1H),7.46-7.38(m,4H),7.14-7.04(m,4H),6.34(s,1H),3.82(s,3H),1.27(s,9H).

[0549] Example 40 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 40)

[0550]

[0551] Referring to Step 1 and Step 2 in Example 39, 4-aminophenol was replaced with 4-amino-2-fluorophenol to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-3-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0552] ESI-MS: m / z = 517.0 [M+H] + .

[0553] 1 H NMR (400MHz, DMSO-d6): δ9.27(s,1H),8.39(s,1H),8.18(s,1H),7.61(dd,J1=8.8Hz,J2=1.6Hz,1H), 7.44-7.39(m,2H),7.30(t,J=8.8Hz,1H),7.11-7.07(m,3H),6.35(s,1H),3.82(s,3H),1.27(s,9H).

[0554] Example 41 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2,6-difluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 41)

[0555]

[0556] Referring to Step 1 and Step 2 in Example 39, 4-aminophenol was replaced with 4-amino-3,5-difluorophenol to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2,6-difluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0557] ESI-MS: m / z = 535.0 [M+H] + .

[0558] 1H NMR (400MHz, DMSO-d6): δ8.87(s,1H),8.72(s,1H),8.22(s,1H),7.46-7.38(m,2H) ,7.23(d,J=8.4Hz,2H),7.10-7.00(m,2H),6.27(s,1H),3.82(s,3H),1.26(s,9H).

[0559] Example 42 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 42)

[0560]

[0561] Referring to Step 1 and Step 2 in Example 39, 4-aminophenol was replaced with 4-amino-3-methylphenol to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0562] ESI-MS: m / z = 513.0 [M+H] + .

[0563] 1 H NMR (400MHz, DMSO-d6): δ9.08(s,1H),8.30(s,1H),8.16(s,1H),7.46-7.38(m,4H),7.14-7.04(m,4H),6.34(s,1H),3.82(s,3H),1.27(s,9H).

[0564] Example 43 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-3-methylphenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 43)

[0565]

[0566] Referring to Step 1 and Step 2 in Example 39, 4-aminophenol was replaced with 4-amino-2-methylphenol to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-3-methylphenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0567] ESI-MS: m / z = 513.0 [M+H]+ .

[0568] 1 H NMR (400MHz, DMSO-d6): δ9.02(s,1H),8.30(s,1H),8.14(s,1H),7.47-7.39(m,2H),7.37(d,J=2.4Hz,1H),7.24(dd,J1 =8.8Hz, J2=2.8Hz,1H),7.13-7.06(m,2H),7.04(d,J=8.4Hz,1H),6.34(s,1H),3.82(s,3H),2.03(s,3H),1.27(s,9H).

[0569] Example 44 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methoxyphenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 44)

[0570]

[0571] Referring to Step 1 and Step 2 in Example 39, 4-aminophenol was replaced with 4-amino-3-methoxyphenol to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methoxyphenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0572] ESI-MS: m / z = 529.0 [M+H] + .

[0573] 1 H NMR (400MHz, DMSO-d6): δ8.95(s,1H),8.59(s,1H),8.18(s,1H),8.09(d,J=8.8Hz,1H),7.43-7.36(m,2H),7.11-7.05( m,2H),6.94(d,J=2.8Hz,1H),6.74(dd,J1=8.8Hz,J2=2.8Hz,1H),6.35(s,1H),3.82(s,3H),3.81(s,3H),1.26(s,9H).

[0574] Example 45 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-chlorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 45)

[0575]

[0576] Referring to Step 1 and Step 2 in Example 39, 4-aminophenol was replaced with 4-amino-3-chlorophenol to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-chlorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0577] ESI-MS: m / z = 533.0 [M+H] + .

[0578] 1 H NMR (400MHz, DMSO-d6): δ9.07(s,1H),8.69(s,1H),8.19(s,1H),8.08(d,J=9.2Hz,1H),7.48-7.38(m ,3H),7.20(dd,J1=9.2Hz,J2=2.8Hz,1H),7.14-7.03(m,2H),6.36(s,1H),3.82(s,3H),1.27(s,9H).

[0579] Example 46 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)phenyl)-3-(3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 46)

[0580]

[0581] Referring to Step 1 in Example 38, 4-amino-6-(4-amino-3-methylphenoxy)pyrimidine-5-carbonitrile was replaced with 4-amino-6-(4-aminophenoxy)pyrimidine-5-carbonitrile to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)phenyl)-3-(3-(tert-butyl)-1-(4-ethoxyphenyl)-1H-pyrazol-5-yl)urea.

[0582] ESI-MS: m / z = 513.0 [M+H] + .

[0583] 1 H NMR (400MHz, DMSO-d6): δ9.15(s,1H),8.38(s,1H),8.16(s,1H),8.00(s,2H),7.45-7.39(m,J2=2.8 Hz,4H),7.12-7.05(m,4H),6.33(s,1H),4.11(q,J=7.2Hz,2H),1.37(t,J=7.2Hz,3H),1.27(s,9H).

[0584] Example 47 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-(pyrrolidin-1-yl)phenyl)-1H-pyrazol-5-yl)urea (Compound 47)

[0585]

[0586] Referring to steps 1 to 3 in Example 1, dimethylamine hydrochloride was replaced by pyrrolidine, and M1 was replaced by M6 to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-(pyrrolidin-1-yl)phenyl)-1H-pyrazol-5-yl)urea.

[0587] ESI-MS: m / z = 552.0 [M+H] + .

[0588] 1 H NMR (400MHz, DMSO-d6): δ8.54(s,1H),8.31(s,1H),8.17(s,1H),7.74(d,J=8.8Hz,1H),7.27-7.23(m,2H),7.04(d,J=2.8Hz,1H),6.9 9(dd,J1=8.8Hz,J2=2.8Hz,1H),6.66-6.62(m,2H),6.30(s,1H),3.29(t,J=6.8Hz,4H),2.17(s,3H),2.00-1.96(m,4H),1.26(s,9H).

[0589] Example 48 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-morpholinophenyl)-1H-pyrazol-5-yl)urea (Compound 48)

[0590]

[0591] Referring to steps 1 to 3 in Example 1, dimethylamine hydrochloride was replaced by morpholine, and M1 was replaced by M6 to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-morpholinophenyl)-1H-pyrazol-5-yl)urea.

[0592] ESI-MS: m / z = 568.0 [M+H] + .

[0593] 1 H NMR (400MHz, DMSO-d6): δ8.64(s,1H),8.29(s,1H),8.17(s,1H),7.73(d,J=8.8Hz,1H),7.36-7.32(m,2H),7.09-7.04(m,3H ), 6.99 (dd, J1 = 8.8Hz, J2 = 2.8Hz, 1H), 6.32 (s, 1H), 3.77 (t, J = 4.8Hz, 4H), 3.18 (t, J = 4.8Hz, 4H), 2.17 (s, 3H), 1.26 (s, 9H).

[0594] Example 49 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)urea (Compound 49)

[0595]

[0596] Referring to steps 1 to 3 in Example 1, M1 was replaced by M6 to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)urea

[0597] ESI-MS: m / z = 526.0 [M+H] + .

[0598] 1 H NMR (400MHz, DMSO-d6): δ8.62(s,1H),8.34(s,1H),8.17(s,1H),7.74(d,J=8.8Hz,1H),7.30-7.26(m,2H),7.04(d,J=2 .8Hz,1H),6.99(dd,J1=8.8Hz,J2=2.8Hz,1H),6.86-6.82(m,2H),6.31(s,1H),2.96(s,6H),2.17(s,3H),1.26(s,9H).

[0599] Example 50 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-(ethyl(methyl)amino)phenyl)-1H-pyrazol-5-yl)urea (Compound 50)

[0600]

[0601] Referring to steps 1 to 3 in Example 1, dimethylamine hydrochloride was replaced by N-methylethylamine hydrochloride, and M1 was replaced by M6 to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-(ethyl(methyl)amino)phenyl)-1H-pyrazol-5-yl)urea.

[0602] ESI-MS: m / z = 540.0 [M + H] + .

[0603] 1 H NMR (400MHz, DMSO-d6): δ8.60(s,1H),8.32(s,1H),8.17(s,1H),7.74(d,J=8.8Hz,1H),7.27-7.24(m,2H),7.04(d,J=2.8Hz,1H),6.98(dd,J1 =8.4Hz, J2=2.8Hz,1H),6.86-6.76(m,2H),6.30(s,1H),3.47(q,J=7.2Hz,2H),2.92(s,3H),2.17(s,3H),1.26(s,9H),1.08(t,J=6.8Hz,3H).

[0604] Example 51 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(1-(4-azetidin-1-yl)phenyl)3-(tert-butyl)-1H-pyrazol-5-yl)urea (Compound 51)

[0605]

[0606] Referring to steps 1 to 3 in Example 1, dimethylamine hydrochloride was replaced with azetidine, and M1 was replaced with M6 to obtain the target compound 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(1-(4-azetidin-1-yl)phenyl)3-(tert-butyl)-1H-pyrazol-5-yl)urea

[0607] ESI-MS: m / z = 538.0 [M+H] + .

[0608] 1H NMR (400MHz, DMSO-d6): δ8.59(s,1H),8.29(s,1H),8.17(s,1H),7.74(d,J=8.8Hz,1H),7.33-7.24(m,2H),7.05(d,J=2.8Hz,1H),6.99 (dd,J1=8.4Hz, J2=2.8Hz,1H),6.58-6.48(m,2H),6.30(s,1H),3.87(t,J=7.2Hz,4H),2.37(q,J=7.2Hz,2H),2.17(s,3H),1.25(s,9H).

[0609] Example 52 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(3-cyano-4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)urea (Compound 52)

[0610]

[0611] Step 1: Synthesis of 3-cyano-4-fluorophenylhydrazine hydrochloride

[0612] Dissolve 3-cyano-4-fluoroaniline (545 mg, 4.00 mmol) in concentrated hydrochloric acid (6 mL), add sodium nitrite (303 mg, 4.40 mmol) in water (1 mL) at -5 °C, maintain the temperature for 40 minutes, cool to -20 °C, add stannous chloride dihydrate (2.70 g, 12.00 mmol) in concentrated hydrochloric acid (2 mL), return to -5 °C and react for 30 minutes. Filter the reaction solution, wash the filter cake with a small amount of ice water, then with a small amount of ice ethyl acetate, and dry to obtain 3-cyano-4-fluorophenylhydrazine hydrochloride 420 mg, light yellow solid, yield 56.1%;

[0613] ESI-MS: m / z = 152.0 [M+H] + .

[0614] Step 2: Synthesis of 5-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)-2-fluorobenzonitrile

[0615] 3-Cyano-4-fluorophenylhydrazine hydrochloride (400 mg, 2.14 mmol) and pivaloyl acetonitrile (267 mg, 2.14 mmol) were dissolved in toluene (10 mL), triethylamine (324 mg, 3.21 mmol) was added, and the system was heated under reflux overnight. The solvent was dried, and the residue was separated by column chromatography, and the eluent was 10-50% ethyl acetate in petroleum ether solution to obtain 500 mg of 5-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)-2-fluorobenzonitrile as a light yellow solid, with a yield of 90.7%;

[0616] ESI-MS: m / z = 259.0 [M+H] + .

[0617] Step 3: Synthesis of 5-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)-2-(dimethylamino)benzonitrile

[0618] 5-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)-2-fluorobenzonitrile (200 mg, 0.77 mmol) was dissolved in DMF (10 mL), cesium carbonate (1.26 g, 3.85 mmol) and dimethylamine hydrochloride (623 mg, 7.75 mmol) were added, and the system was heated to 100 ° C for 4 hours. The system was cooled to room temperature, quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), the organic phases were combined, the organic phases were washed with water once (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography, the eluent was 0-30% ethyl acetate in petroleum ether solution, and 5-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)-2-(dimethylamino)benzonitrile 67 mg was obtained as a yellow solid with a yield of 30.6%;

[0619] ESI-MS: m / z = 284.0 [M+H] + .

[0620] Step 4: Synthesis of phenyl (3-(tert-butyl)-1-(3-cyano-4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)carbamate

[0621] 5-(5-amino-3-(tert-butyl)-1H-pyrazol-1-yl)-2-(dimethylamino)benzonitrile (67 mg, 0.24 mmol) was dissolved in dichloromethane (5 mL), triethylamine (36 mg, 0.36 mmol) was added, phenyl chloroformate (44 mg, 0.28 mmol) was added dropwise under ice bath, and the temperature was maintained for 4 hours. The reaction solution was quenched with water, extracted with dichloromethane three times (3 times, 20 mL each time), the organic phases were combined, washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 65 mg of phenyl (3-(tert-butyl)-1-(3-cyano-4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)carbamate, with a yield of 68.1%.

[0622] ESI-MS: m / z = 404.0 [M + H] + .

[0623] Step 5: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(3-cyano-4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)urea

[0624] Phenyl (3-(tert-butyl)-1-(3-cyano-4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)carbamate (65 mg, 0.16 mmol), 4-amino-6-(4-amino-3-methylphenoxy)pyrimidine-5-carbonitrile (39 mg, 0.16 mmol) and triethylamine (24 mg, 0.24 mmol) were dissolved in tetrahydrofuran (5 mL), and the temperature was raised to 70 ° C for 4 hours. The system was cooled to room temperature, quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), and the organic phases were combined, washed with water once (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with 0-3% methanol in dichloromethane as the eluent to give 13 mg of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(3-cyano-4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)urea in a yield of 14.7%.

[0625] ESI-MS: m / z = 551.0 [M+H] + .

[0626] 1H NMR (400MHz, DMSO-d6): δ8.70(s,1H),8.28(s,1H),8.17(s,1H),7.75(d,J=2.8Hz,1H),7.66-7.62(m,2H),7.18(d,J=8. 8Hz,1H),7.06(d,J=2.8Hz,1H),6.99(dd,J1=8.8Hz,J2=2.8Hz,1H),6.33(s,1H),3.04(s,6H),2.17(s,3H),1.27(s,9H).

[0627] Example 53 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)-3-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 53)

[0628]

[0629] Step 1: Synthesis of 3-methoxy-4-nitrophenylhydrazine

[0630] Dissolve 4-fluoro-2-methoxy-1-nitrobenzene (600 mg, 3.51 mmol) in acetonitrile (10 mL), add potassium carbonate (968 mg, 7.02 mmol), dropwise add 85% hydrazine hydrate (158 mg, 4.21 mmol), and heat to 60 ° C for 6 hours. The reaction solution was concentrated under reduced pressure, and the residue was extracted with water and ethyl acetate (3 times, 20 mL each time). The organic phases were combined, washed once with saturated brine (20 ml), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure to obtain 417 mg of 3-methoxy-4-nitrophenylhydrazine, with a yield of 64.6%;

[0631] ESI-MS: m / z = 184.0 [M + H] + .

[0632] Step 2: Synthesis of 3-(tert-butyl)-1-(3-methoxy-4-nitrophenyl)-1H-pyrazol-5-amine

[0633] 3-Methoxy-4-nitrophenylhydrazine (400 mg, 2.19 mmol) and pivaloyl acetonitrile (273 mg, 2.19 mmol) were dissolved in toluene (10 mL), triethylamine (332 mg, 3.29 mmol) was added, and the system was heated to reflux overnight. The solvent was dried, and the residue was separated by column chromatography, and the eluent was 10-50% ethyl acetate in petroleum ether solution to obtain 602 mg of 3-(tert-butyl)-1-(3-methoxy-4-nitrophenyl)-1H-pyrazole-5-amine, with a yield of 95.0%;

[0634] ESI-MS: m / z = 291.0 [M+H] + .

[0635] Step 3: Synthesis of phenyl(3-(tert-butyl)-1-(3-methoxy-4-nitrophenyl)-1H-pyrazol-5-yl)carbamate

[0636] Dissolve (tert-butyl)-1-(3-methoxy-4-nitrophenyl)-1H-pyrazole-5-amine (200 mg, 0.69 mmol) in dichloromethane (5 mL), add triethylamine (104 mg, 1.03 mmol), add phenyl chloroformate (108 mg, 0.69 mmol) dropwise under ice bath, and keep the temperature for 4 hours. The reaction solution is quenched with water, extracted with dichloromethane three times (3 times, 20 mL each time), the organic phases are combined, washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate is concentrated under reduced pressure to obtain 210 mg of phenyl (3-(tert-butyl)-1-(3-methoxy-4-nitrophenyl)-1H-pyrazole-5-yl) carbamate, with a yield of 74.3%.

[0637] ESI-MS: m / z = 411.0 [M+H] + .

[0638] Step 4: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(3-methoxy-4-nitrophenyl)-1H-pyrazol-5-yl)urea

[0639] Phenyl (3-(tert-butyl)-1-(3-methoxy-4-nitrophenyl)-1H-pyrazol-5-yl) carbamate (210 mg, 0.51 mmol), 4-amino-6-(4-amino-3-methylphenoxy) pyrimidine-5-carbonitrile (123 mg, 0.51 mmol) and triethylamine (78 mg, 0.77 mmol) were dissolved in tetrahydrofuran (5 mL), and the temperature was raised to 70 ° C for 4 hours. The system was cooled to room temperature, quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), and the organic phases were combined, washed with water once (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with 0-3% methanol in dichloromethane as the eluent to give 223 mg of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(3-methoxy-4-nitrophenyl)-1H-pyrazol-5-yl)urea in a yield of 78.2%.

[0640] ESI-MS: m / z = 558.0 [M+H] + .

[0641] Step 5: Synthesis of 1-(1-(4-amino-3-methoxyphenyl)-3-(tert-butyl)-1H-pyrazol-5-yl)-3-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)urea

[0642] 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(3-methoxy-4-nitrophenyl)-1H-pyrazol-5-yl)urea (220 mg, 0.39 mmol) was dissolved in ethanol (10 mL) and water (1 mL), and ammonium chloride (42 mg, 0.79 mmol) and reduced iron powder (111 mg, 1.97 mmol) were added. The system was heated to 70 ° C and reacted for 3 hours. The mixture was cooled to room temperature, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with a 0-3% methanol in dichloromethane solution as the eluent to give 80 mg of 1-(1-(4-amino-3-methoxyphenyl)-3-(tert-butyl)-1H-pyrazol-5-yl)-3-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)urea in a yield of 38.5%.

[0643] ESI-MS: m / z = 528.0 [M+H] + .

[0644] Step 6: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)-3-methoxyphenyl)-1H-pyrazol-5-yl)urea

[0645] 1-(1-(4-amino-3-methoxyphenyl)-3-(tert-butyl)-1H-pyrazol-5-yl)-3-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)urea (80 mg, 0.15 mmol) was dissolved in dichloromethane (5 mL), and aqueous formaldehyde solution (150 μL) and a drop of glacial acetic acid were added. After stirring at room temperature for 8 hours, sodium triacetoxyborohydride (127 mg, 0.60 mmol) was added, and the system was stirred at room temperature for 4 hours. The reaction solution was quenched with water, extracted with dichloromethane three times (3 times, 20 mL each time), the organic phases were combined, washed once with saturated brine (20 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography with a 0-3% methanol in dichloromethane solution as the eluent to give 15 mg of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-methylphenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)-3-methoxyphenyl)-1H-pyrazol-5-yl)urea in a yield of 17.8%.

[0646] ESI-MS: m / z = 556.0 [M+H] + .

[0647] 1 H NMR (400MHz, DMSO-d6): δ8.72(s,1H),8.34(s,1H),8.17(s,1H),7.74(d,J=8.8Hz,1H),7.05-7. 01(m,2H),6.99-6.97(m,3H),6.34(s,1H),3.84(s,3H),2.74(s,6H),2.17(s,3H),1.27(s,9H).

[0648] Example 54 Synthesis of 1-(4-((6-amino-5-ethynylpyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 54)

[0649]

[0650] Step 1: Synthesis of 6-(4-amino-3-fluorophenoxy)-5-((trimethylsilyl)ethynyl)pyrimidin-4-amine

[0651] 6-(4-amino-3-fluorophenoxy)-5-iodopyrimidin-4-amine (280 mg, 0.81 mmol) was dissolved in tetrahydrofuran (10 mL), and trimethylsilyl acetylene (317 mg, 3.24 mmol), bistriphenylphosphine palladium dichloride (56 mg, 0.08 mmol), cuprous iodide (31 mg, 0.16 mmol), triphenylphosphine (26 mg, 0.08 mmol) and triethylamine (16 mg, 0.16 mmol) were added in sequence, the system was replaced with nitrogen, and the temperature was raised to 65 ° C for 3 hours. After cooling to room temperature, the reaction solution was quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), and the organic phases were combined, dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure and the residue was purified by column chromatography with 0-30% ethyl acetate in petroleum ether as the eluent to give 140 mg of 6-(4-amino-3-fluorophenoxy)-5-((trimethylsilyl)ethynyl)pyrimidin-4-amine in a yield of 54.7%.

[0652] ESI-MS: m / z = 317.0 [M+H] + .

[0653] Step 2: Synthesis of 6-(4-amino-3-fluorophenoxy)-5-ethynylpyrimidin-4-amine

[0654] Dissolve 6-(4-amino-3-fluorophenoxy)-5-((trimethylsilyl)ethynyl)pyrimidin-4-amine (140 mg, 0.45 mmol) in acetonitrile (4 mL), add cesium fluoride (269 mg, 1.77 mmol), and heat to 40 ° C for 20 minutes. Quench with water, extract with ethyl acetate three times (3 times, 20 mL each time), combine the organic phases, wash the organic phase with water once (20 mL), wash with saturated brine (50 mL), dry with anhydrous sodium sulfate, and filter. The filtrate is concentrated under reduced pressure. The residue is purified by column chromatography, the eluent is 0-3% methanol in dichloromethane, and 103 mg of 6-(4-amino-3-fluorophenoxy)-5-ethynylpyrimidin-4-amine is obtained, and the yield is 95.4%.

[0655] ESI-MS: m / z = 245.0 [M+H] + .

[0656] Step 3: Synthesis of 1-(4-((6-amino-5-ethynylpyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea

[0657] 6-(4-amino-3-fluorophenoxy)-5-ethynylpyrimidin-4-amine (30 mg, 0.13 mmol), phenyl (3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl) carbamate (47 mg, 0.13 mmol) and triethylamine (39 mg, 0.39 mmol) were dissolved in tetrahydrofuran (5 mL), and the temperature was raised to 70 ° C for 4 hours. The system was cooled to room temperature, quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), and the organic phases were combined, washed with water once (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography with 0-3% methanol in dichloromethane as the eluent to give 18 mg of 1-(4-((6-amino-5-ethynylpyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea in a yield of 28.4%.

[0658] ESI-MS: m / z = 516.0 [M+H] + .

[0659] 1H NMR (400MHz, DMSO-d6): δ8.93(d,J=2.0Hz,1H),8.74(s,1H),8.09(t,J=9.2Hz,1H),8.01(s,1H),7.44-7.38(m,2H),7.19( dd, J1=12.0Hz, J2=2.8Hz,1H),7.13-7.06(m,2H),6.95-6.92(m,1H),6.36(s,1H),4.64(s,1H),3.82(s,3H),1.27(s,9H).

[0660] Example 55 Synthesis of (1-(4-((6-amino-5-cyclopropylpyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 55)

[0661]

[0662] Step 1: Synthesis of 6-(4-amino-3-fluorophenoxy)-5-cyclopropylpyrimidin-4-amine

[0663] 6-(4-amino-3-fluorophenoxy)-5-iodopyrimidin-4-amine (100 mg, 0.29 mmol), cyclopropylboronic acid (80 mg, 0.87 mmol), palladium acetate (10 mg, 0.029 mmol), 4,5-bis(diphenylphosphino)-9,9-dimethylxanthene (34 mg, 0.058 mmol) and cesium carbonate (290 mg, 0.87 mmol) were added to the flask in sequence, 10 mL of toluene and 1 mL of water were added to dissolve, the system was replaced with nitrogen three times, and microwave reaction was carried out at 110 ° C for 1 hour. The reaction solution was cooled and filtered, the filtrate was concentrated under reduced pressure, and the residue was separated by column chromatography, the eluent was 0-90% ethyl acetate petroleum ether solution, and 6-(4-amino-3-fluorophenoxy)-5-cyclopropylpyrimidin-4-amine 50 mg was obtained, and the yield was 66.7%;

[0664] ESI-MS: m / z = 261.0 [M+H] + ;

[0665] Step 2: Synthesis of (1-(4-((6-amino-5-cyclopropylpyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea

[0666] 6-(4-amino-3-fluorophenoxy)-5-cyclopropylpyrimidin-4-amine (50 mg, 0.19 mmol) was dissolved in tetrahydrofuran (10 mL), phenyl (3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl) carbamate (140 mg, 0.38 mmol) and triethylamine (58 mg, 0.57 mmol) were added, and the system was heated to 70 ° C for 2 hours. The system was cooled to room temperature, quenched with water, extracted with ethyl acetate three times (3 times, 20 mL each time), the organic phases were combined, the organic phases were washed with water once (20 mL), washed with saturated brine (50 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure. The residue was purified by column chromatography, with 0-3% methanol in dichloromethane as the eluent, to give 23 mg of (1-(4-((6-amino-5-cyclopropylpyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea, with a yield of 22.5%;

[0667] ESI-MS: m / z = 532.0 [M + H] + ;

[0668] 1 H NMR (400MHz, DMSO-d6): δ8.91(d,J=2.4Hz,1H),8.74(s,1H),8.03(t,J=9.2Hz,1H),7.90(s,1H),7.48-7.34(m,2H),7.12-7.02(m,3 H),6.90-6.82(m,1H),6.73(s,2H),6.35(s,1H),3.82(s,3H),1.40-1.35(m,1H),1.26(s,9H),1.00-0.91(m,2H),0.63-0.54(m,2H).

[0669] Example 56 Synthesis of 1-(4-((6-amino-5-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 56)

[0670]

[0671] Referring to Step 1 and Step 3 in Example 54, trimethylsilyl acetylene was replaced with 2-methylbut-3-yn-2-ol to obtain the target compound 1-(4-((6-amino-5-(3-hydroxy-3-methylbut-1-yn-1-yl)pyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0672] ESI-MS: m / z = 574.0 [M+H] + ;

[0673] 1 H NMR (400MHz, DMSO-d6): δ8.93(d,J=2.0Hz,1H),8.74(s,1H),8.10(t,J=8.8Hz,1H),8.00(s,1H),7.42-7.40(m,2H),7.17(dd,J1=12.0Hz ,J2=2.8Hz,1H),7.11-7.07(m,2H),6.94(dd,J1=8.8Hz,J2=1.6Hz,1H),6.37(s,1H),5.53(s,1H),3.83(s,3H),1.47(s,6H),1.27(s,9H).

[0674] Example 57 Synthesis of 1-(4-((6-amino-5-(3,3-dimethylbut-1-yn-1-yl)pyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 57)

[0675]

[0676] Referring to Step 1 and Step 3 in Example 54, trimethylsilyl acetylene was replaced with 3,3-dimethylbut-1-yne to obtain the target compound 1-(4-((6-amino-5-(3,3-dimethylbut-1-yne-1-yl)pyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0677] ESI-MS: m / z = 572.0 [M+H] + ;

[0678] 1 H NMR (400MHz, DMSO-d6): δ8.92(s,1H),8.73(s,1H),8.06(t,J=9.2Hz,1H),7.98(s,1H),7.43-7.39(m,2H),7.18(dd,J 1=12.0Hz, J2=2.8Hz,1H),7.11-7.07(m,2H),6.94-6.90(m,1H),6.36(s,1H),3.82(s,3H),1.29(s,9H),1.26(s,9H).

[0679] Example 58 Synthesis of 1-(4-((6-amino-5-(cyclopropylethynyl)pyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (Compound 58)

[0680]

[0681] Referring to Step 1 and Step 3 in Example 54, trimethylsilyl acetylene was replaced with ethynylcyclopropane to obtain the target compound 1-(4-((6-amino-5-(cyclopropylethynyl)pyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea.

[0682] ESI-MS: m / z = 556.0 [M+H] + ;

[0683] 1 H NMR (400MHz, DMSO-d6): δ8.92(d,J=2.4Hz,1H),8.74(s,1H),8.09(t,J=9.2Hz,1H),7.95(s,1H),7.44-7.39(m,2H),7.17(dd,J1=12.0 Hz,J2=2.4Hz,1H),7.12-7.07(m,2H),6.93-6.89(m,1H),6.37(s,1H),3.82(s,3H),1.61-1.57(m,1H),1.27(s,9H),0.88-0.82(m,4H).

[0684] Example 59 Synthesis of 1-(4-((6-amino-5-ethynylpyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)urea (Compound 59)

[0685]

[0686] Referring to Step 3 in Example 54, phenyl(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)carbamate was replaced with phenyl(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)carbamate to give the target compound 1-(4-((6-amino-5-ethynylpyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-(dimethylamino)phenyl)-1H-pyrazol-5-yl)urea.

[0687] ESI-MS: m / z = 529.0 [M+H] + ;

[0688] 1 H NMR (400MHz, DMSO-d6): δ8.99(d,J=2.4Hz,1H),8.71(s,1H),8.11(t,J=8.8Hz,1H),8.01(s,1H),7.30-7.24(m,2H),7.20(dd,J1=1 2.0Hz, J2=2.8Hz, 1H), 6.95 (dt, J1=8.8Hz, J2=2.0Hz, 1H), 6.87-6.79 (m, 2H), 6.34 (s, 1H), 4.65 (s, 1H), 2.96 (s, 6H), 1.26 (s, 9H).

[0689] Example 60 Synthesis of 1-(4-((2-aminopyridin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 60)

[0690]

[0691] Step 1: Synthesis of tert-butyl (2-fluoro-4-((2-nitropyridin-4-yl)oxy)phenyl)carbamate (Ie-1)

[0692] Dissolve 4-chloro-2-nitropyridine (Ic-1, 1.58 g, 10 mmol) in 15 mL N, N-dimethylformamide, add intermediate Id-1 (2.27 g, 10 mmol) and cesium carbonate (4.89 mg, 15 mmol), and stir at 90 ° C for 3 hours. After the reaction is completed, add 50 mL of water to the system, extract with ethyl acetate (3 times, 50 mL each time), combine the organic phases, wash twice with water and then with saturated brine, concentrate under reduced pressure, and separate the residue by column chromatography, eluent 0-30% ethyl acetate: petroleum ether, to obtain 3.04 g of Ie-1, with a yield of 87.2%;

[0693] ESI-MS: m / z = 350.0 [M + H] + .

[0694] Step 2: Synthesis of 2-fluoro-4-((2-nitropyridin-4-yl)oxy)aniline (If-1)

[0695] The intermediate Ie-1 (3.04 g, 8.7 mmol) was dissolved in dichloromethane (30 mL), 4 mL of trifluoroacetic acid was added, and the mixture was stirred at room temperature for 2 hours. The reaction solution was dried by spin drying, saturated sodium carbonate solution (30 mL) was added, and the aqueous layer was extracted twice with ethyl acetate (2 times, 30 mL each time), the organic layers were combined, dried over anhydrous sodium sulfate, and spin dried to obtain 2.12 g of If-1, with a yield of 97.9%.

[0696] ESI-MS: m / z = 250.0 [M + H] + .

[0697] Step 3: Synthesis of 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((2-nitropyridin-4-yl)oxy)phenyl)urea (I-1-pro1)

[0698] To 5 mL of tetrahydrofuran, add intermediate If-1 (249 mg, 1 mmol), intermediate Ib-1 (335 mg, 1 mmol) and triethylamine (0.42 mL, 3 mmol) in sequence, heat to 60 ° C and stir for 6 hours. After the reaction is completed, the solvent is dried by rotary evaporation, the residue is extracted with water and ethyl acetate, the organic phases are combined, washed once with saturated brine, dried over anhydrous sodium sulfate, and dried by rotary evaporation. The obtained oil is directly used in the next step;

[0699] ESI-MS: m / z = 491.0 [M+H] + ;

[0700] Step 4: Synthesis of 1-(4-((2-aminopyridin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 60)

[0701] The residue was dissolved in 10 mL of ethanol, and stannous chloride dihydrate (902 mg, 4 mmol) and 1 mL of concentrated hydrochloric acid were added, and the temperature was raised to 60°C and stirred for 4 hours. The mixture was concentrated under reduced pressure, and a saturated NaHCO3 solution was added to adjust the pH to a weak alkaline state. The mixture was extracted with ethyl acetate, and the organic phases were combined, washed once with saturated saline, dried over anhydrous sodium sulfate, and spin-dried. The residue was separated by a full preparative liquid chromatography (column: Shim-pack GIST C18 5 μm*20*250 mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20 min), to obtain 214 mg of the target compound 60, with a yield of 46.5%.

[0702] ESI-MS: m / z = 461.0 [M+H] + .

[0703] Example 61 Synthesis of 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((2-(methylamino)pyridin-4-yl)oxy)phenyl)urea (Compound 61)

[0704]

[0705] Step 1: 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((2-(methylamino)pyridin-4-yl)oxy)phenyl)urea (Compound 61)

[0706] Compound 60 (50 mg, 0.11 mmol) was dissolved in 3 mL of dichloromethane, and 27 μL of formaldehyde solution and a drop of glacial acetic acid were added, and the mixture was stirred at room temperature for 8 h. NaBH3CN (10 mg, 0.16 mmol) was added under ice bath, and the mixture was reacted at room temperature overnight. The reaction solution was extracted with saturated sodium carbonate solution and dichloromethane, and the organic phases were combined and washed once with saturated brine, dried over anhydrous sodium sulfate, and the residue was separated by full preparative liquid chromatography (column: Shim-pack GIST C18 5 μm*20*250 mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20 min), to obtain 34 mg of the target compound 61, with a yield of 66.0%.

[0707] ESI-MS: m / z = 475.0 [M + H] + .

[0708] Example 62 Synthesis of 1-(4-((2-amino-3-methylpyridin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 62)

[0709]

[0710] The preparation method of the target compound 62 is similar to that of Example 60, whereby intermediate Ic-1 is replaced by Ic-2, condensed with intermediate Id-1, and then the Boc protecting group is removed, followed by condensation with intermediate Ib-1, and finally the nitro group is reduced to obtain the target compound 62.

[0711] ESI-MS: m / z = 475.0 [M + H] + .

[0712] Example 63 Synthesis of 1-(4-((2-aminopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 63)

[0713]

[0714] The preparation method of the target compound 63 is similar to that of I-1-pro1 in Example 60, except that the intermediate Ic-1 is replaced by Ic-3, the Boc protecting group is removed after condensation with the intermediate Id-1, and the target compound 63 is obtained after condensation with the intermediate Ib-1.

[0715] ESI-MS: m / z = 462.0 [M+H] + .

[0716] 1 H NMR (400MHz, DMSO-d6): δ8.93(d,J=2.0Hz,1H),8.81(s,1H),8.12(d,J=5.6Hz,1H),8.06(t,J=8.28Hz,1H),7.55-7.51(m,4H),7.45 -7.41(m,1H),7.22(dd,J1=11.6Hz,J2=2.4Hz,1H),6.98-6.95(m,1H),6.68(s,2H),6.40(s,1H),6.14(d,J=5.6Hz,1H),1.28(s,9H).

[0717] Example 64 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 64)

[0718]

[0719] The preparation method of the target compound 64 is similar to that of Example 63, except that the intermediate Ic-3 is replaced by Ic-4, the Boc protecting group is removed after condensation with the intermediate Id-1, and the target compound 64 is obtained after condensation with the intermediate Ib-1.

[0720] ESI-MS: m / z = 487.0 [M+H] + .

[0721] 1 H NMR (400MHz, DMSO-d6): δ8.98(s,1H),8.86(s,1H),8.19(s,1H),8.12(t,J=7.2Hz,1H),7.57-7.51(m,4H),7.45- 7.41 (m, 1H), 7.31 (dd, J1 = 11.6Hz, J2 = 2.4Hz, 1H), 7.04 (dd, J1 = 9.2Hz, J2 = 2.0Hz, 1H), 6.41 (s, 1H), 1.28 (s, 9H).

[0722] Example 65 1-(4-((6-amino-5-methylpyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 65)

[0723]

[0724] The preparation method of the target compound 65 is similar to that of Example 63, except that the intermediate Ic-3 is replaced by Ic-5, the Boc protecting group is removed after condensation with the intermediate Id-1, and the target compound 65 is obtained after condensation with the intermediate Ib-1.

[0725] ESI-MS: m / z = 476.0 [M + H] + .

[0726] 1 H NMR (400MHz, DMSO-d6): δ8.89(s,1H),8.81(s,1H),8.03(t,J=9.2Hz,1H),7.91(s,1H),7.57-7.51(m,4H),7.45-7.41 (m,1H),7.01(dd,J1=12.0Hz,J2=2.8Hz,1H),6.89-6.86(m,1H),6.72(s,2H),6.40(s,1H),2.00(s,3H),1.28(s,9H).

[0727] Example 66 1-(4-((6-amino-5-cyano-2-methoxypyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 66)

[0728]

[0729] Step 1: Synthesis of tert-butyl (4-((6-amino-5-cyano-2-(methylthio)pyrimidin-4-yl)oxy)-2-fluorophenyl)carbamate (Ie-6)

[0730] The preparation method of intermediate Ie-6 is similar to that of Ie-1, whereby intermediate Ic-1 is replaced by Ic-6 and condensed with intermediate Id-1 to obtain Ie-6.

[0731] ESI-MS: m / z = 392.0 [M+H] + .

[0732] Step 2: Synthesis of 4-amino-6-(4-amino-3-fluorophenoxy)-2-(methylthio)pyrimidine-5-carbonitrile (If-6)

[0733] The preparation method of intermediate If-6 is similar to that of If-1, wherein intermediate Ie-1 is replaced by Ie-6, and the Boc protecting group is removed to obtain If-6.

[0734] ESI-MS: m / z = 292.0 [M+H] + ;

[0735] Step 3: Synthesis of 1-(4-((6-amino-5-cyano-2-(methylthio)pyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (I-7-pro1)

[0736] The intermediate If-6 (400 mg, 1.37 mmol) was dissolved in 5 mL of tetrahydrofuran, and the intermediate Ib-1 (460 mg, 1.37 mmol) and triethylamine (572 μL, 4.12 mmol) were added, and the reaction solution was stirred at 60°C for 4 hours. After the reaction was completed, the solvent was dried, and water and ethyl acetate were added for extraction. The organic phases were combined, washed once with saturated brine, dried over anhydrous sodium sulfate, and dried. The residue was separated and purified by column chromatography, and the eluent was 0-40% ethyl acetate in petroleum ether to obtain 473 mg (yield 64.7%) of the target product as a white solid.

[0737] ESI-MS: m / z = 533.0 [M+H] + .

[0738] Step 4: Synthesis of 1-(4-((6-amino-5-cyano-2-(methylsulfonyl)pyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (I-7-pro2)

[0739] Under ice bath, m-CPBA (288 mg, 1.33 mmol) was slowly added to the dichloromethane solution of intermediate I-7-pro1 (470 mg, 0.88 mmol), warmed to room temperature, and stirred for 3 h. A small amount of sodium thiosulfate aqueous solution (3 mL) and water (10 mL) were added to the reaction solution, and the aqueous layer was extracted with ethyl acetate (2 times, 10 mL each time), the organic phases were combined, dried over anhydrous sodium sulfate, and spin-dried. The residue was separated and purified by column chromatography, and the eluent was 0-40% ethyl acetate in petroleum ether to obtain 412 mg of product (yield 83.1%), which was directly used in the next step.

[0740] ESI-MS: m / z = 565.0 [M+H] + .

[0741] Step 5: Synthesis of 1-(4-((6-amino-5-cyano-2-methoxypyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 66)

[0742] I-7-pro2 (100 mg, 0.18 mmol) synthesized in step 2 was dissolved in N, N-dimethylformamide (3 mL), sodium methoxide (21 mg, 0.39 mmol) was added, and the reaction was stirred at room temperature for 8 h. Water (15 mL) was added to the reaction solution, and the aqueous layer was extracted with ethyl acetate (3 times, 10 mL each time), and the organic phases were combined, washed with water and saturated brine once, dried over anhydrous sodium sulfate, and then spin-dried. The residue was separated by full preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min), and 34 mg of the target product (yield 36.6%) was obtained.

[0743] ESI-MS: m / z = 517.0 [M+H] + .

[0744] 1 H NMR (400 MHz, DMSO-d6): δ8.99 (s, 1H), 8.87 (s, 1H), 8.12 (t, J = 9.2 Hz, 1H), 7.56-7.53 (m, 4H), 7.46-7.43 (m, 2H), 7.41-7.39 (m, 1H), 7.30-7.26 (m, 1H), 7.04-7.01 (m, 1H), 6.40 (s, 1H), 3.72 (s, 3H), 1.28 (s, 9H). Example 67 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-(3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-8-yl)oxy)phenyl)urea (Compound 67)

[0745]

[0746] Step 1: Synthesis of tert-butyl (2-fluoro-4-((4-(4-methoxybenzyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-8-yl)oxy)phenyl)carbamate (Ie-7)

[0747] The preparation method of intermediate Ie-7 is similar to that of Ie-1, whereby intermediate Ic-1 is replaced by Ic-7 and condensed with intermediate Id-1 to obtain Ie-7.

[0748] ESI-MS: m / z = 496.0 [M + H] + .

[0749] Step 2: Synthesis of 8-(4-amino-3-fluorophenoxy)-4-(4-methoxybenzyl)-2H-pyrido[3,2-b][1,4]oxazin-3(4H)-one (Intermediate If-7)

[0750] The preparation method of intermediate If-7 is similar to that of If-1, whereby intermediate Ie-1 is replaced by Ie-7 and the Boc protecting group is removed to obtain If-7.

[0751] ESI-MS: m / z = 396.0 [M+H] + .

[0752] Step 3: Synthesis of 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((4-(4-methoxybenzyl)-3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-8-yl)oxy)phenyl)urea (Intermediate I-8-pro1)

[0753] The intermediate If-7 (70 mg, 0.18 mmol), the intermediate Ib-1 (65 mg, 0.20 mmol) and triethylamine (27 mg, 0.27 mmol) were dissolved in tetrahydrofuran (5 mL), and the mixture was heated to 60 ° C and stirred for 3 h. The mixed solution was quenched with water, filtered and extracted three times with ethyl acetate (3 times, 20 mL each time), the combined organic phase was washed with water (10 mL), washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by preparative thin layer chromatography, the developing solvent was 40% ethyl acetate in petroleum ether, and 40 mg of the target intermediate I-8-pro1 was obtained, with a yield of 35.5%.

[0754] ESI-MS: m / z = 637.0 [M+H] + .

[0755] Step 4: Synthesis of 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((3-oxo-3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-8-yl)oxy)phenyl)urea (Compound 67)

[0756] The intermediate I-8-pro1 (40 mg, 0.10 mmol) was dissolved in dichloromethane (1 ml), trifluoroacetic acid (0.5 mL) and trifluoromethanesulfonic acid (0.5 mL) were added dropwise, and the mixture was stirred at room temperature for 1 h. The reaction solution was concentrated under reduced pressure, and the residue was separated by full preparative liquid chromatography (column: Shim-pack GIST C18 5 μm*20*250 mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20 min) to obtain 11 mg of the target product with a yield of 33.6%.

[0757] ESI-MS: m / z = 517.0 [M+H] + .

[0758] 1 H NMR (400MHz, DMSO-d6): δ11.33(s,1H),8.93(s,1H),8.82(s,1H),8.09(t,J=9.2Hz,1H),7.82(d,J=5.6Hz,1H),7.57-7.51(m,4H),7.44 -7.41(m,1H),7.16(dd,J1=12.0Hz,J2=2.8Hz,1H),6.93(d,J=8.8Hz,1H),6.56(d,J=5.6Hz,1H),6.39(s,1H),4.64(s,2H),1.28(s,9H).

[0759] Example 68 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(4-((3,4-dihydro-2H-pyrido[3,2-b][1,4]oxazin-8-yl)oxy)-2-fluorophenyl)urea (Compound 68)

[0760]

[0761] Compound 67 (51 mg, 0.10 mmol) was dissolved in ultra-dry tetrahydrofuran (5 mL), and borane dimethyl sulfide solution (0.55 mL, 0.20 mmol) was added dropwise at room temperature. The mixture was heated to 60°C and stirred for 1 h. After the mixture was cooled to room temperature, methanol was added to quench it, and it was extracted three times with ethyl acetate (3 times, 20 mL each time). The combined organic phase was washed with water (10 mL), washed with saturated brine (10 mL), dried over anhydrous sodium sulfate, and filtered. The filtrate was concentrated under reduced pressure, and the residue was separated by full preparative liquid chromatography (column: Shim-packGIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20 min) to obtain 6 mg of the target product with a yield of 11.5% as a white solid.

[0762] ESI-MS: m / z = 503.0 [M+H] + .

[0763] 1 H NMR (400MHz, DMSO-d6): δ8.87(d,J=2.0Hz,1H),8.80(s,1H),8.01(t,J=9.2Hz,1H),7.56-7.48(m,4H),7.44-7.40(m,1H),7.00(dd,J1=12.0Hz,J2 =2.8Hz,1H),6.84(d,J=2.4Hz,1H),6.81-6.78(m,1H),6.38(s,1H),6.11 (d, J=5.6Hz, 1H), 4.09 (t, J=4.0Hz, 2H), 3.41-3.38 (m, 2H), 1.27 (s, 9H).

[0764] Example 69 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(2-fluoro-4-((7-oxo-7,8-dihydro-1,8-naphthyridin-4-yl)oxy)phenyl)urea (Compound 69)

[0765]

[0766] The preparation method of the target compound 69 is similar to that of Example 63, except that the intermediate Ic-3 is replaced by Ic-8, the Boc protecting group is removed after condensation with the intermediate Id-1, and the target compound 69 is obtained after condensation with the intermediate Ib-1.

[0767] ESI-MS: m / z = 513.0 [M+H] + .

[0768] Example 70 1-(4-((2-aminothiazol-5-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 70)

[0769]

[0770] Step 1: Synthesis of tert-butyl (4-((2-((benzyloxy)carbonyl)amino)thiazol-5-yl)oxy)-2-fluorophenyl)carbamate (Ie-9)

[0771] The preparation method of intermediate Ie-9 is similar to that of Ie-1, whereby intermediate Ic-1 is replaced by Ic-9 and condensed with intermediate Id-1 to obtain Ie-9;

[0772] ESI-MS: m / z = 460.0 [M + H] + .

[0773] Step 2: Synthesis of benzyl (5-(4-amino-3-fluorophenoxy)thiazol-2-yl)carbamate (If-9)

[0774] The preparation method of intermediate If-9 is similar to that of If-1, whereby intermediate Ie-1 is replaced by Ie-9 and the Boc protecting group is removed to obtain If-9;

[0775] ESI-MS: m / z = 360.0 [M + H] + .

[0776] Step 3: Synthesis of benzyl (5-(4-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)thiazol-2-yl)carbamate (Intermediate I-11-pro1)

[0777] The intermediate If-9 (115 mg, 0.32 mmol), the intermediate Ib-1 (96 mg, 0.32 mmol) and triethylamine (65 mg, 0.64 mmol) were dissolved in tetrahydrofuran (5 mL), and the mixture was heated to 75 ° C and stirred for 6 h. The reaction solution was quenched with water, filtered and extracted with ethyl acetate three times (3 times, 20 mL each time), the combined organic phase was washed with water (9 mL), washed with saturated brine (9 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was purified by column chromatography, the eluent was 0-50% ethyl acetate in petroleum ether solution, and 165 mg of the target intermediate I-11-pro1 was obtained, with a yield of 85.9%.

[0778] ESI-MS: m / z = 601.0 [M+H] + .

[0779] Step 4: Synthesis of 1-(4-((2-aminothiazol-5-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 70)

[0780] The intermediate I-11-pro1 (120 mg, 0.20 mmol) was dissolved in 33% hydrobromic acid in acetic acid solution (2 mL) and stirred at room temperature for 6 h. The reaction solution was concentrated under reduced pressure, and the residue was separated by full preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20 min) to obtain 57 mg of the target product with a yield of 61.2%.

[0781] ESI-MS: m / z = 467.0 [M+H] + .

[0782] 1 H NMR (400MHz, DMSO-d6): δ8.84(d,J=2.0Hz,1H),8.76(s,1H),8.00(t,J=9.2Hz,1H),7.56-7.49(m,4H),7.44- 7.40(m,1H),7.04(dd,J1=12.0Hz,J2=2.8Hz,1H),6.90-6.87(m,3H),6.74(s,1H),6.38(s,1H),1.27(s,9H).

[0783] Example 71 5-(4-(3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)thiazole-2-carboxamide (Compound 71)

[0784]

[0785] Step 1: Synthesis of tert-butyl (4-((2-cyanothiazol-5-yl)oxy)-2-fluorophenyl)carbamate (Ie-10)

[0786] The preparation method of intermediate Ie-10 is similar to that of Ie-1, whereby intermediate Ic-1 is replaced by Ic-10 and condensed with intermediate Id-1 to obtain Ie-10.

[0787] ESI-MS: m / z = 336.0 [M+H] + .

[0788] Step 2: Synthesis of 5-(4-amino-3-fluorophenoxy)thiazole-2-carbonitrile (If-10)

[0789] The preparation method of intermediate If-10 is similar to that of If-1, wherein intermediate Ie-1 is replaced by Ie-10, and the Boc protecting group is removed to obtain If-10.

[0790] ESI-MS: m / z = 236.0 [M+H] + .

[0791] Step 3: Synthesis of 1-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)-3-(4-((2-cyanothiazol-5-yl)oxy)-2-fluorophenyl)urea (Intermediate I-12-pro1)

[0792] The preparation method of intermediate I-12-pro1 is similar to that of I-1-pro1, whereby intermediate If-1 is replaced by If-10 and condensed with intermediate Ib-1 to obtain I-12-pro1.

[0793] ESI-MS: m / z = 477.0 [M+H]+ .

[0794] Step 4: Synthesis of 5-(4-(3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)thiazole-2-carboxamide (Compound 71)

[0795] The intermediate I-12-pro1 (30 mg, 0.05 mmol) was dissolved in dimethyl sulfoxide (2 mL), potassium carbonate (42 mg, 0.30 mmol) and 30% hydrogen peroxide (15 mg, 0.42 mmol) were added and stirred at room temperature for 1 h. Water was added to the reaction solution, and it was filtered and extracted three times with ethyl acetate (3 times, 10 mL each time), the combined organic phase was washed with water (10 mL), washed with saturated brine (5 mL), dried over anhydrous sodium sulfate, filtered, and the filtrate was concentrated under reduced pressure. The residue was separated by full preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min), and the target product 12 mg was obtained with a yield of 38.5%.

[0796] ESI-MS: m / z = 495.0 [M + H] + .

[0797] 1 H NMR (400MHz, DMSO-d6): δ8.98(d,J=2.5Hz,1H),8.83(s,1H),8.14-8.09(m,2H),7.83(s,1H),7.65(s,1H),7.57-7. 51m,4H),7.45-7.43(m,1H),7.33(dd,J1=12.0Hz,J2=3.2Hz,1H),7.09(d,J=9.2Hz,1H),6.39(s,1H),1.27(s,9H).

[0798] Example 72 5-(4-(3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)thiazole-2-carboxylic acid (Compound 72)

[0799]

[0800] The intermediate I-12-pro1 (30 mg, 0.05 mmol) was dissolved in concentrated hydrochloric acid (2 mL), heated to 80 ° C and stirred for 4 h. The reaction solution was distilled under reduced pressure, and the residue was separated by full preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20 min) to obtain 8 mg of the target product with a yield of 32.3%.

[0801] ESI-MS: m / z = 494.0 [MH] - .

[0802] Example 73 1-(4-((5-amino-1,3,4-thiadiazol-2-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 73)

[0803]

[0804] The preparation method is similar to that of Example 70, except that the raw material Ic-9 is replaced by Ic-11, the Boc protecting group is removed after condensation with the intermediate Id-1, and then the mixture is condensed with the intermediate Ib-1, and finally the Cbz protecting group is removed to obtain the target product 73;

[0805] ESI-MS: m / z = 468.0 [M + H] + .

[0806] Example 74 1-(4-((2-aminooxazol-5-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl) (Compound 74)

[0807]

[0808] The preparation method is similar to that of Example 70, except that the raw material Ic-9 is replaced by Ic-12, the Boc protecting group is removed after condensation with the intermediate Id-1, and then the reaction is condensed with the intermediate Ib-1, and finally the Cbz protecting group is removed to obtain the target product 74.

[0809] ESI-MS: m / z = 451.0 [M+H] + .

[0810] Example 75 4-(4-(3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)ureido)-3-fluorophenoxy)-N-methylpicolinamide (Compound 75)

[0811]

[0812] The preparation method of the target compound 75 is similar to that of Example 63, except that intermediate Ic-3 is replaced by Ic-13, the Boc protecting group is removed after condensation with intermediate Id-1, and the target compound 75 is obtained after condensation with intermediate Ib-1.

[0813] ESI-MS: m / z = 503.0 [M+H] + .

[0814] 1 H NMR (400MHz, DMSO-d6): δ9.03 (d, J=2.0Hz, 1H), 8.88 (s, 1H), 8.80-8.77 (m, 1H), 8 .53(d,J=5.6Hz,1H),8.21(t,J=9.2Hz,1H),7.58-7.51(m,4H),7.46-7.42(m,1H), 7.41(d,J=2.8Hz,1H),7.33(dd,J1=12.0Hz,J2=2.8Hz,1H),7.18(dd,J1=5.6Hz,J 2=2.4Hz,1H),7.06-7.03(m,1H),6.41(s,1H),2.80(d,J=4.8Hz,3H),1.28(s,9H).

[0815] Example 76 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-chlorophenyl)-3-(3-(tert-butyl)-1-phenyl-1H-pyrazol-5-yl)urea (Compound 76)

[0816]

[0817] The preparation method of the target compound 76 is similar to that of Example 64, except that the intermediate Id-1 is replaced by Id-2, the Boc protecting group is removed after condensation, and then condensed with the intermediate Ib-1 to obtain II-1.

[0818] ESI-MS: m / z = 503.0 [M+H] + .

[0819] Examples 77-84 Synthesis of target compounds 77-84

[0820] The preparation methods of target compounds 77 to 84 are similar to those of Example 64, except that the raw material Id-1 is replaced with the corresponding Id series raw materials. The obtained products are shown in the table:

[0821]

[0822]

[0823] Example 85 Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-fluorophenyl)-1H-pyrazol-5-yl)urea (Compound 85)

[0824]

[0825] Step 1: Synthesis of phenyl (4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)carbamate (Intermediate Ig-1)

[0826] The intermediate If-4 (366 mg, 1.45 mmol) was dissolved in 6 mL of tetrahydrofuran, and phenyl chloroformate (227 mg, 1.45 mmol) was added dropwise under ice bath. After reacting for 2 h, the system was spin-dried and the residue was separated by column chromatography with 10-40% ethyl acetate in petroleum ether as the eluent to obtain 480 mg of Ig-1 with a yield of 90.6%.

[0827] ESI-MS: m / z = 366.0 [M+H] + .

[0828] 1 H NMR (400MHz, DMSO-d6): δ9.99(s,1H),8.22(s,1H),8.05(s,2H),7.77(t,J=8.4Hz,1H),7.4 6-7.41(m,2H),7.36(dd,J1=11.2Hz,J2=2.8Hz,1H),7.28-7.22(m,3H),7.12-7.09(m,1H).

[0829] Step 2: Synthesis of 1-(4-((6-amino-5-cyanopyrimidin-4-yl)oxy)-2-fluorophenyl)-3-(3-(tert-butyl)-1-(4-methoxyphenyl)-1H-pyrazol-5-yl)urea (III-1)

[0830] The intermediate Ia-2 (50.00 mg, 0.20 mmol) was dissolved in 2 mL of tetrahydrofuran, and the intermediate Ig-1 (74.26 mg, 0.20 mmol) and triethylamine (61.87 mg, 0.61 mmol) were added, and the system was stirred at 60°C for 16 hours. After the reaction was completed, the reaction solution was dried by spin drying, and the residue was separated by full preparative liquid chromatography (column: Shim-pack GIST C18 5μm*20*250mm; mobile phase: A: water (0.1% formic acid v / v), B: acetonitrile; B%: 10%-100%, 20min), to obtain 45 mg of the target compound 85, with a yield of 42.9%.

[0831] ESI-MS: m / z = 517.0 [M+H] + .

[0832] 1 H NMR (400MHz, DMSO-d6): δ8.99(s,1H),8.78(s,1H),8.19(s,1H),8.14(t,J=8.8Hz,1H),7.43-7.40(m,2H),7.3 1(dd, J1=12.0Hz, J2=2.8Hz,1H),7.10-7.08(m,2H),7.04-7.01(m,1H),6.37(s,1H),3.82(s,3H),1.26(s,9H).

[0833] Examples 86-98 Synthesis of target compounds 86-98

[0834] The preparation methods of target compounds 86-98 are similar to those of Example 85, except that the raw material Ia-2 is replaced with the corresponding Ia series raw materials, and condensed with the intermediate Ig-1 to obtain the compounds as shown in the following table:

[0835]

[0836]

[0837]

[0838] Control compound:

[0839]

[0840] Prepared by referring to the preparation method of compound Ib-4 in WO2021226547.

[0841] Biological activity test

[0842] Example 1 In vitro IL-1β release inhibition activity test of the compound

[0843] In this example, compound Ib-4 in patent WO2021226547 was used as a positive control, and PMA (phorbol 12-myristate 13-acetate) was used to differentiate the human monocytic cell line THP-1 into mature macrophages, and then the cells were stimulated with LPS (lipopolysaccharide). After 4 hours of stimulation, the target compound was added and cultured for 1 hour, and then nigericin was added and cultured for another 1 hour. The cell culture supernatant was collected, and the interleukin IL-1β content was detected by double antibody sandwich ELISA after low-speed centrifugation (1000xg) for 10 minutes, and the inhibition rate of the compound on IL-1β release was calculated. The final results were input into Graphpad Prism for plotting to obtain the curve and IC50 , and then evaluate the activity of the compound in blocking the binding of NEK7 and NLRP3. The results are shown in Table 1 below:

[0844] Table 1

[0845]

[0846]

[0847] From the in vitro IL-1β secretion inhibition activity data in the table, it can be seen that the N,N-diaryl urea derivatives described in the present invention generally show a strong effect of inhibiting NEK7 activity and blocking the NLRP3 inflammasome signaling pathway to release IL-1β, and therefore have good application prospects.

[0848] Example 2 Pharmacokinetic properties of the compound

[0849] Detection method: Male SD rats, weighing about 200g, were randomly divided into 2 groups, 3 rats in each group, one group was intravenously injected with 0.5mg / kg compound once, and the other group was gavaged with 5mg / kg compound once. Blood was collected at the specified time points, and plasma was separated and stored in a -80℃ refrigerator for later use. After the above plasma samples were precipitated with acetonitrile for protein, the supernatant was extracted and mixed with water in a ratio of 1:1. 10μL was taken for LC-MS / MS detection, and the average value was calculated. The experimental data are shown in Table 2 below:

[0850] Table 2

[0851]

[0852] It can be seen from the data in the table that the representative compounds of the present invention have good plasma exposure and oral bioavailability after oral administration and have good oral administration potential.

[0853] Example 3 In vitro AIM-2 inflammasome pathway agonist activity of the compounds

[0854] Experimental purpose: To test the effect of compounds on the activation of AIM2 inflammasome in BMDM cells

[0855] The control compound MCC950 was purchased from Jiangsu Aikon.

[0856] Experimental method: 1x 10 5Mouse bone marrow mononuclear cells were induced with RPMI (10% FBS, 1% Penstrep) containing 40ng / mL GM-CSF for 7 days to form bone marrow-derived macrophages. The culture medium was discarded, and RPMI containing 100ng / mL LPS was added for 3 hours, and the test compounds of various concentrations were added for 1 hour. 1μg / mL poly(dA:dT) was transfected with Lipofectamine2000 and incubated for 3 hours. The supernatant was collected and the IL-1β release was detected using an IL-1β ELISA kit. Fold-change and T.TEXT were analyzed using EXCEL.

[0857] The experimental results are as follows Figure 1 As shown by Figure 1 It can be seen from the data that the NLRP3 inhibitor MCC950 does not activate the AIM-2 inflammasome pathway, while the series of compounds of the present invention can effectively and selectively activate the AIM-2 inflammasome pathway, and can promote the release of IL-1β and the occurrence of cell pyroptosis in the presence of dsDNA, and can be used to treat related diseases such as viral and bacterial infections, nerve damage or malignant tumors.

Claims

1. A compound having a structure represented by general formula (II), or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule or metabolite thereof: in: m is selected from 0, 1, 2 or 3; X 1 , Y 1 Each independently selected from N or CR 2 ; Z is selected from N or CR 2a ; L is selected from O, CR 1a R 1b or NR 1c ; Cy is selected from the group consisting of one or more R Y Substituted 4-10 membered heterocyclic group, C 6-12 Aryl or 5-14 membered heteroaryl; R Y is selected from hydrogen, halogen, cyano, hydroxyl, amino, mercapto, oxo, or may be replaced by one or more R 3a Substituted C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio, C 1-6 Alkylamino, 4-10 membered heterocyclic, C 6-12 Aryl, 5-14 membered heteroaryl; or any two R Y and the atoms they are connected to form C 3 -C 6 Cycloalkyl or 4-8 membered heterocyclic group, the C 3 -C 6 The cycloalkyl or 4-8 membered heterocyclic group may be optionally substituted with one or more R 3a replace; R 1 Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkylsulfone, -CO-NH-(C 1-6 Alkyl), -CO-NH-(C 3-6 Cycloalkyl), 4-10 membered heterocyclic group, C 6-12 Aryl or 5-14 membered heteroaryl; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkylsulfone, 4-10 membered heterocyclic group, C 6-12 The aryl or 5-14 membered heteroaryl may be optionally substituted by one or more of the following substituents: halogen, cyano, hydroxy, amino, mercapto, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio, C 1-6 Alkylamino, 4-10 membered heterocyclic, C 6-12 Aryl or 5-14 membered heteroaryl; R 2 Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkylsulfone, -CO-NH-(C 1-6 Alkyl), -CO-NH-(C 3-6 cycloalkyl) or a 4-8 membered heterocyclic group; said C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 The alkylsulfone group or the 4-8 membered heterocyclic group is unsubstituted or substituted by one or more of the following substituents: halogen, cyano, hydroxyl, amino, mercapto, oxo, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio or C 1-6 Alkylamino; R 3 is selected from cyano, ethynyl or cyclopropyl, wherein the ethynyl or cyclopropyl may be optionally replaced by C 1-6 Alkyl, C 1-6 Hydroxyalkyl, 4-10 membered heterocyclic group or C 3-8 Cycloalkyl substitution; R 1a and R 1b are each independently selected from hydrogen, halogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, hydroxyl, amino, cyano, C 1-6 Alkoxy or C 1-6 Alkylamino; Or, R 1a and R 1b The atoms to which they are connected may also be connected to each other to form a 3-8 membered aliphatic ring or heterocyclic ring, wherein the aliphatic ring and heterocyclic ring may be saturated or unsaturated; R 1c Selected from hydrogen, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl or C 3-6 Cycloalkyl; R 2a is selected from hydrogen, halogen, cyano, hydroxy, difluoromethoxy, trifluoromethoxy, amino, thiol, trifluoromethylthio, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio or C 1-6 Alkylamino; R 3a , R 4a Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 Alkylsulfone or a 4-8 membered heterocyclic group.

2. The compound according to claim 1, or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, metabolite thereof, It is characterized in that The compound has a structure shown in the following formula (III): Among them, the R 1 , Cy, X 1 , Y 1 ,m,R 3 , L, R 4a The definition is as defined in claim 1.

3. The compound according to claim 2, or a pharmaceutically acceptable salt, isotope derivative, solvate, or a stereoisomer, geometric isomer, tautomer, or a prodrug molecule or metabolite thereof, It is characterized in that The compound has a structure as shown in the following formula (IIIA) or (IIIB): Among them, the R 1 , Cy, X 1 , Y 1 ,m,R 3 , R 4a The definition is as defined in claim 1.

4. The compound according to claim 2 or 3, or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, metabolite thereof, It is characterized in that The X 1 or Y 1 Each independently selected from CR 2 ; said R 2 Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl, C 1-6 Haloalkyl, C 2-6 Alkenyl, C 2-6 Alkynyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino or C 1-6 Alkylsulfone group, the R 4a Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl or C 1-6 Alkoxy, wherein m is 1 or 2.

5. The compound according to claim 4, or a pharmaceutically acceptable salt, isotope derivative, solvate, or a stereoisomer, geometric isomer, tautomer, or a prodrug molecule or metabolite thereof, It is characterized in that The R 2 is selected from hydrogen, halogen, methyl or methoxy.

6. The compound according to claim 4 or 5, or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, metabolite thereof, It is characterized in that The X 1 , Y 1 Each is independently selected from CH.

7. The compound according to any one of claims 1 to 6, or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, metabolite thereof, It is characterized in that The R 3 is selected from cyano, ethynyl or cyclopropyl, wherein the ethynyl and cyclopropyl groups may be optionally replaced by one or more C 1-6 Alkyl or C 1-6 Hydroxyalkyl substituted.

8. The compound according to claim 7, or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, metabolite thereof, It is characterized in that The R 3 Selected from 9. The compound according to any one of claims 1 to 8, or a pharmaceutically acceptable salt, isotope derivative, solvate, or a stereoisomer, geometric isomer, tautomer, or a prodrug molecule or metabolite thereof, It is characterized in that The R 1 Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, thiol, C 1-6 Alkyl, C 3-6 Cycloalkyl or 4-10 membered heterocyclic group; 1-6 Alkyl, C 3-6 The cycloalkyl or 4-10 membered heterocyclic group may be optionally substituted by one or more of the following substituents: hydrogen, halogen, cyano, hydroxy, amino, mercapto, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio, C 1-6 Alkylamino or 4-10 membered heterocyclic group, preferably, the R 1 Each independently selected from C 1-6 Alkyl or C 3-6 Cycloalkyl; said C 1-6 Alkyl, C 3-6 The cycloalkyl group may be optionally substituted with one or more of the following substituents: hydrogen, cyano, hydroxy, amino, mercapto, oxo, C 1-6 Alkyl, C 1-6 Haloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio or C 1-6 Alkylamino.

10. The compound according to claim 9, or a pharmaceutically acceptable salt, isotope derivative, solvate, or a stereoisomer, geometric isomer, tautomer, or a prodrug molecule or metabolite thereof, It is characterized in that The R 1 Selected from 11. The compound according to claim 1-10, or a pharmaceutically acceptable salt, isotope derivative, solvate, or a stereoisomer, geometric isomer, tautomer, or a prodrug molecule or metabolite thereof, It is characterized in that The Cy is selected from one or more R Y substituted phenyl, cyclohexyl or pyridyl; said R Y Each is independently selected from hydrogen, halogen, cyano, hydroxyl, amino, mercapto, oxo, or may be replaced by one or more R 3a Substituted C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylsulfone, C 1-6 Alkylthio, C 1-6 Alkylamino or 4-10 membered heterocyclic group; or any two R Y and the atoms they are connected to form C 3 -C 6 Cycloalkyl or 4-8 membered heterocyclic group, the C 3 -C 6 The cycloalkyl or 4-8 membered heterocyclic group may be optionally substituted with one or more R 3a Substitution; said R 3a Selected from hydrogen, halogen, cyano, hydroxyl, amino, mercapto, C 1-6 Alkyl, C 3-6 Cycloalkyl, C 1-6 Alkoxy, C 1-6 Alkylthio, C 1-6 Alkylamino, C 1-6 an alkylsulfone group, or a 4-8 membered heterocyclic group.

12. The compound according to claim 1-11, or a pharmaceutically acceptable salt, isotope derivative, solvate, or a stereoisomer, geometric isomer, tautomer, or a prodrug molecule or metabolite thereof, It is characterized in that Cy is selected from the following groups:

13. The compound according to any one of claims 1 to 12, or a pharmaceutically acceptable salt, isotopic derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, metabolite thereof, It is characterized in that The compound is selected from the following structural compounds: or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, or a metabolite thereof.

14. A pharmaceutical composition, It is characterized in that The pharmaceutical composition contains a therapeutically effective amount of the compound according to any one of claims 1 to 13 or a pharmaceutically acceptable salt, isotope derivative, solvate thereof, or a stereoisomer, geometric isomer, tautomer thereof, or a prodrug molecule, metabolite thereof.

15. Use of the compound according to any one of claims 1 to 13 or its pharmaceutically acceptable salt, isotopic derivative, solvate, or stereoisomer, geometric isomer, tautomer, or prodrug molecule, metabolite thereof, or the pharmaceutical composition according to claim 14 in the preparation of a medicament for treating diseases or disorders mediated by NEK7 or associated with AIM-2 inflammasomes and related diseases or disorders.